

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	Release by Secured Party (Second Lien)
CONVEYING PARTY DATA	
Name	Execution Date
Morgan Stanley Senior Funding, Inc.	09/24/2012
RECEIVING PARTY DATA	
Name:	Alkermes, Inc.
Street Address:	852 Winter Street
City:	Waltham
State/Country:	MASSACHUSETTS
Postal Code:	02451
Name:	Alkermes Pharma Ireland Limited
Street Address:	Monskland
City:	Athlone Co. Westmeath
State/Country:	IRELAND
Name:	Alkermes Controlled Therapeutics Inc.
Street Address:	852 Winter Street
City:	Waltham
State/Country:	MASSACHUSETTS
Postal Code:	02451
PROPERTY NUMBERS Total: 414	
Property Type	Number
Patent Number:	5688801
Patent Number:	5965168
Patent Number:	6110921
Patent Number:	6368632
Patent Number:	6544559
Patent Number:	6803055

OP \$16560.00 5688801

Patent Number:	7118763
Patent Number:	7547452
Patent Number:	5650173
Patent Number:	5654008
Patent Number:	5792477
Patent Number:	5916598
Patent Number:	6110503
Patent Number:	6290983
Patent Number:	6403114
Patent Number:	6194006
Patent Number:	6379703
Patent Number:	6596316
Patent Number:	6495164
Patent Number:	6667061
Patent Number:	7371406
Patent Number:	7799345
Application Number:	12856198
Patent Number:	6331317
Patent Number:	6395304
Patent Number:	6537586
Patent Number:	6713090
Patent Number:	6861016
Patent Number:	6264987
Patent Number:	6379704
Patent Number:	6534092
Patent Number:	6471995
Patent Number:	6830737
Patent Number:	6884372
Patent Number:	6495166
Patent Number:	6540393
Patent Number:	6705757
Patent Number:	6939033
Patent Number:	7300671
Patent Number:	7510730
Patent Number:	6362308

	6703477
Patent Number:	7074883
Patent Number:	7247319
Patent Number:	6824822
Patent Number:	7223440
Patent Number:	7524530
Patent Number:	7875310
Application Number:	12967757
Patent Number:	6800663
Patent Number:	7089681
Application Number:	12051395
Application Number:	12140542
Application Number:	61529705
Patent Number:	7164005
Patent Number:	7462365
Application Number:	12289857
Patent Number:	7456254
Application Number:	10592769
Patent Number:	7563871
Patent Number:	7612176
Application Number:	11578712
Application Number:	12483871
Application Number:	12585574
Application Number:	12713036
Patent Number:	7279579
Application Number:	11860677
Application Number:	12241404
Patent Number:	6987111
Application Number:	12251656
Patent Number:	7919499
Application Number:	13037713
Application Number:	12371334
Application Number:	12727784
Application Number:	12823007
Application Number:	12978298

	12978178
Application Number:	12823102
Application Number:	12978273
Application Number:	12978274
Application Number:	12978240
Application Number:	12903462
Application Number:	13100515
Application Number:	13096679
Application Number:	13168497
Application Number:	13215718
Application Number:	61427026
Application Number:	61442629
Application Number:	61472016
Application Number:	61495203
Application Number:	61502721
Application Number:	61527986
Application Number:	61454008
Patent Number:	6500448
Patent Number:	5711968
Patent Number:	6165508
Patent Number:	6780434
Patent Number:	5922253
Patent Number:	6153129
Patent Number:	6358443
Patent Number:	6726860
Patent Number:	7037450
Patent Number:	5817343
Patent Number:	6183781
Patent Number:	5916597
Patent Number:	6514533
Patent Number:	6555525
Patent Number:	6451347
Patent Number:	6444223
Patent Number:	6713087
Patent Number:	6284283

	6428815
Patent Number:	6465425
Patent Number:	6479065
Patent Number:	6499361
Patent Number:	7097857
Patent Number:	7074432
Patent Number:	6569458
Patent Number:	7658998
Application Number:	11826694
Patent Number:	5506206
Patent Number:	5260478
Patent Number:	5264610
Patent Number:	5328404
Patent Number:	5298262
Patent Number:	5302401
Patent Number:	5451393
Patent Number:	5322679
Patent Number:	5466433
Patent Number:	5326552
Patent Number:	5447710
Patent Number:	5330739
Patent Number:	5470583
Patent Number:	5346688
Patent Number:	5346702
Patent Number:	5352459
Patent Number:	5384107
Patent Number:	5494683
Patent Number:	5401492
Patent Number:	5429824
Patent Number:	5466440
Patent Number:	5643552
Patent Number:	5472683
Patent Number:	5573749
Patent Number:	5488133
Patent Number:	5500204

	5503723
Patent Number:	5510118
Patent Number:	5518187
Patent Number:	5518738
Patent Number:	5521218
Patent Number:	5525328
Patent Number:	5534270
Patent Number:	5543133
Patent Number:	5571536
Patent Number:	5560931
Patent Number:	5560932
Patent Number:	5565188
Patent Number:	5705194
Patent Number:	5569448
Patent Number:	5573750
Patent Number:	5573783
Patent Number:	5580579
Patent Number:	5585108
Patent Number:	5587143
Patent Number:	5591456
Patent Number:	5593657
Patent Number:	5603916
Patent Number:	5622938
Patent Number:	5628981
Patent Number:	6432381
Application Number:	10175851
Patent Number:	5662883
Patent Number:	5665331
Patent Number:	5668196
Patent Number:	5670136
Patent Number:	5716642
Patent Number:	5718388
Patent Number:	5718919
Patent Number:	5747001
Patent Number:	5834025

	RE41884
Patent Number:	5862999
Patent Number:	5936030
Patent Number:	6045829
Patent Number:	6068858
Patent Number:	6221400
Patent Number:	6153225
Patent Number:	6165506
Patent Number:	6264922
Application Number:	09577489
Application Number:	12081670
Patent Number:	7521068
Patent Number:	6811767
Application Number:	12320431
Patent Number:	6270806
Patent Number:	6267989
Patent Number:	6656504
Application Number:	09337675
Application Number:	11979231
Application Number:	12483188
Application Number:	13102795
Patent Number:	6428814
Patent Number:	7288267
Patent Number:	7850995
Patent Number:	6431478
Patent Number:	6745962
Patent Number:	6991191
Patent Number:	6316029
Application Number:	10667470
Application Number:	12068706
Patent Number:	6375986
Patent Number:	6592903
Patent Number:	6969529
Patent Number:	7244451
Patent Number:	6582285

	10246751
Patent Number:	6742734
Patent Number:	6976647
Patent Number:	7575184
Application Number:	09952032
Application Number:	11802158
Application Number:	11979251
Application Number:	12121443
Patent Number:	7459283
Application Number:	12292091
Application Number:	11275069
Application Number:	10035324
Patent Number:	7713551
Application Number:	11928250
Application Number:	11928278
Application Number:	11928289
Application Number:	12076247
Application Number:	12117982
Application Number:	12870722
Application Number:	12870745
Application Number:	12870749
Patent Number:	7101576
Application Number:	10878623
Application Number:	11093149
Application Number:	11472556
Application Number:	12826557
Patent Number:	7276249
Patent Number:	7320802
Application Number:	11710607
Application Number:	11802542
Application Number:	11802567
Application Number:	11979230
Application Number:	12058497
Application Number:	11367716
Patent Number:	7763278

	12704426
Application Number:	10784900
Application Number:	12788203
Application Number:	10705227
Application Number:	10619539
Application Number:	13044450
Application Number:	10654600
Patent Number:	7198795
Patent Number:	7695739
Application Number:	12729018
Patent Number:	7390505
Application Number:	13189299
Application Number:	10420927
Application Number:	11979253
Patent Number:	7842232
Application Number:	10895405
Application Number:	10697703
Application Number:	13193545
Application Number:	12292092
Application Number:	10697716
Application Number:	10701064
Application Number:	10712259
Application Number:	11980720
Application Number:	12292395
Application Number:	10677857
Patent Number:	7879360
Application Number:	10979792
Patent Number:	7910577
Application Number:	12333233
Application Number:	13024315
Application Number:	12232895
Application Number:	11633088
Application Number:	11377650
Application Number:	11376554
Application Number:	11387068

	11402264
Application Number:	11402257
Application Number:	11436887
Application Number:	11980719
Application Number:	11437833
Application Number:	12052436
Application Number:	11363266
Application Number:	11275775
Application Number:	12071849
Application Number:	12484073
Application Number:	13039249
Application Number:	11361055
Application Number:	11354249
Application Number:	12544197
Application Number:	11325626
Application Number:	11372227
Application Number:	11446589
Application Number:	11446564
Application Number:	11446565
Application Number:	11448984
Application Number:	11802427
Application Number:	11481257
Application Number:	11520059
Application Number:	11520058
Application Number:	11761900
Application Number:	11775002
Application Number:	11129807
Application Number:	12331052
Application Number:	12329566
Application Number:	13110647
Application Number:	11262672
Application Number:	11373629
Application Number:	11569483
Application Number:	11329893
Application Number:	11568841

	11571379
Application Number:	11558202
Application Number:	11568925
Application Number:	11422226
Patent Number:	5505962
Patent Number:	5641745
Patent Number:	5364620
Patent Number:	5616345
Patent Number:	5336504
Patent Number:	5370879
Patent Number:	5540938
Patent Number:	5580580
Patent Number:	5533995
Patent Number:	6066339
Patent Number:	6228398
Patent Number:	6730325
Patent Number:	6902742
Patent Number:	6793936
Application Number:	10827689
Application Number:	11372857
Patent Number:	7465462
Patent Number:	7021163
Application Number:	12626001
Application Number:	12626085
Application Number:	12626036
Application Number:	11568891
Application Number:	11569481
Application Number:	13044225
Patent Number:	6908626
Application Number:	12407684
Application Number:	11297737
Application Number:	11571377
Application Number:	11568698
Application Number:	11569206
Application Number:	11568825

	11568835
Patent Number:	5641515
Application Number:	11671276
Application Number:	11672263
Application Number:	11479013
Application Number:	11776770
Application Number:	12049046
Application Number:	11768154
Application Number:	11768169
Patent Number:	5332113
Application Number:	10528727
Application Number:	12757005
Application Number:	12757024
Application Number:	12209728
Application Number:	12397924
Application Number:	12788196
Patent Number:	5242406
Patent Number:	5356632
Patent Number:	5380272
Patent Number:	5871125
Patent Number:	6312409
Patent Number:	6078842
Patent Number:	6157858
Patent Number:	6317630
Patent Number:	D454194
Patent Number:	6719719
Patent Number:	5527288
Patent Number:	5997501
Patent Number:	5814020
Patent Number:	5858001
Patent Number:	6261272
Patent Number:	6346095
Patent Number:	6530900
Patent Number:	6186982
Patent Number:	6500150

	6824529
Patent Number:	6843782
Patent Number:	6275717
Patent Number:	6000548
Patent Number:	6585707
Patent Number:	6595956
Patent Number:	7384413
Application Number:	12121545
Application Number:	13184479
Application Number:	13184473
Patent Number:	6520941
Patent Number:	7530964
Patent Number:	6572740
Patent Number:	6759057
Patent Number:	5948441
Patent Number:	5626873
Patent Number:	5525232
Patent Number:	5716526
Patent Number:	5662930
Patent Number:	5614214
Patent Number:	5591123
Patent Number:	5358483
Patent Number:	5372579

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 212-225-2415

Email: dilan@cgsh.com

Correspondent Name: Daniel Ilan

Address Line 1: One Liberty Plaza c/o Cleary Gottlieb

Address Line 4: New York, NEW YORK 10006

NAME OF SUBMITTER:	Megan St. Ledger
	This document serves as an Oath/Declaration (37 CFR 1.63).

Total Attachments: 39

source=Sept 16 PSA Release (with signatures)#page1.tif

[illegible]

**TERMINATION AND RELEASE OF SECURITY INTEREST
IN PATENTS**

This Termination and Release of Security Interest in Patents (this “**Release**”) is granted on this 24th day of September, 2012, by Morgan Stanley Senior Funding, Inc. (“**Morgan Stanley**”), as collateral agent for the Secured Parties under the security agreements referenced below, in favor of Alkermes, Inc., a corporation organized under the laws of the Commonwealth of Pennsylvania, located at 852 Winter Street, Waltham, Massachusetts; Alkermes Pharma Ireland Limited, a private limited company organized under the laws of the Republic of Ireland (registered number 448848), located at Monksland, Athlone Co. Westmeath, Ireland; and Alkermes Controlled Therapeutics Inc., a corporation organized under the laws of the Commonwealth of Pennsylvania, located at 852 Winter Street, Waltham, Massachusetts (together, “**Alkermes**” or the “**Borrowers**”), with respect to the Patents (as defined below).

W I T N E S S E T H :

WHEREAS, the Borrowers and Morgan Stanley are party to a Second Lien Guarantee and Collateral Agreement dated as of September 16, 2011, in favor of Morgan Stanley;

WHEREAS, pursuant to the Second Lien Guarantee and Collateral Agreement, on September 16, 2011, Morgan Stanley, as collateral agent, and Borrowers entered into a Patent Security Agreement, which was recorded with the U.S. Patent and Trademark Office (the “**USPTO**”) on September 29, 2011, at Reel/Frame 026994/0245 (the “**2011 Patent Security Agreement**”);

WHEREAS, pursuant to the 2011 Patent Security Agreement, Morgan Stanley received a security interest in all of Borrowers’ rights, titles and interests in the United States and throughout the world in the Patent Collateral (as this term is defined in the 2011 Patent Security Agreement), including, without limitation, those patents and patent applications set forth on Schedules A and B hereto; and

WHEREAS, Morgan Stanley desires to release any and all security interests, and any other lien, it has in the Patent Collateral to Alkermes.

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Morgan Stanley hereby agrees as follows:


1. Morgan Stanley hereby releases, terminates and discharges, without representation, recourse or warranty whatsoever, each security interest in the Patent Collateral that was granted to Morgan Stanley under the 2011 Patent Security Agreement. Morgan Stanley acknowledges and agrees that the 2011 Patent Security Agreement has been terminated.

2. The parties hereto authorize and request that (i) with respect to the Patent Collateral listed on Schedule A, the Director of Patents and Trademarks of the United States of America and (ii) with respect to the Patent Collateral listed on Schedule B, the appropriate officer in the Republic of Ireland, record this Release against the Patent Collateral. Morgan Stanley agrees to perform, at the Borrowers' expense, all further acts and execute and deliver all further documents and/or instruments that may be reasonably necessary to carry out the provisions of this Release.
3. This Release shall be governed by and construed in accordance with the law of the State of New York.
4. This Release shall be binding upon Morgan Stanley's representatives, successors, assigns and transferees.

[Remainder of Page Intentionally Blank]

IN WITNESS WHEREOF, the undersigned has caused this Release to be executed by its duly authorized representatives as of the date first above written.

MORGAN STANLEY SENIOR FUNDING, INC.

By 
Name: Stephen B. King
Title: VP
Date: 9/24/12

STATE OF New York
COUNTY OF New York


SS.:

On this 24th day of September, 2012, before me, the undersigned, a notary public in and for said state and county, personally appeared Stephen B. King, personally known to me (or proved to me on the basis of satisfactory evidence), to be the individual who executed the foregoing instrument on behalf of VP as the VP of such company and acknowledged to me that the execution and delivery of said instrument was duly authorized by said company.

P Morgan Stanley Senior Funding, Inc.

Julie G. Floyd
Notary Public

(Affix Seal Below)



SCHEDULE A

ASSIGNMENT REEL FRAME: 026994/0245

Alkermes Patent Schedule September 2011

Case #: 000166.0051

Title: MICROENCAPSULATED 3-PIPERIDINYL-SUBSTITUTED 1,2-BENZISOXAZOLES AND 1,2-BENZISOTHIAZOLES

Owner: ALKERMES, INC. and JANSSEN PHARMACEUTICA

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	01	DIV	Granted	08/403,432	14-Mar-1995	5,688,801	18-Nov-1997	18-Nov-2014
US	03	CON	Granted	09/005,549	12-Jan-1998	5,965,168	12-Oct-1999	19-Nov-2013
US	04	CON	Granted	09/252,486	18-Feb-1999	6,110,921	29-Aug-2000	19-Nov-2013
US	05	CON	Granted	09/578,908	26-May-2000	6,368,632	09-Apr-2002	19-Nov-2013
US	06	DIV	Granted	10/058,072	29-Jan-2002	6,544,559	08-Apr-2003	19-Nov-2013
US	07	DIV	Granted	10/359,226	06-Feb-2003	6,803,055	12-Oct-2004	19-Nov-2013
US	08	DIV	Granted	10/920,422	18-Aug-2004	7,118,763	10-Oct-2006	19-Nov-2013
US	11	REX	Granted	90/007,907	26-Jan-2006	5,688,801	18-Nov-1997	18-Nov-2014
US	12	REX	Granted	90/008,151	28-Aug-2006	6,368,632	23-Oct-2007	19-Nov-2013
US	13	REX	Granted	90/008,212	12-Sep-2006	6,110,921	04-Mar-2008	19-Nov-2013
US	14	REX	Granted	90/008,216	12-Sep-2006	5,965,168	22-Apr-2008	19-Nov-2013
US	16	CON	Granted	11/826,384	13-Jul-2007	7,547,452	16-Jun-2009	19-Nov-2013

Alkermes Patent Schedule

September 2011

Case #: 000166.0053

Title: PREPARATION OF BIODEGRADABLE MICROPARTICLES CONTAINING A BIOLOGICALLY ACTIVE AGENT

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent#	Issue Date	Expiration Date
US	00	CON	Granted	08/725,439	03-Oct-1996	5,650,173	22-Jul-1997	19-Nov-2013
US	01	CON	Granted	08/729,277	10-Oct-1996	5,654,008	05-Aug-1997	19-Nov-2013

Alkermes Patent Schedule

September 2011

Case #: 000166.0063

Title: PREPARATION OF EXTENDED SHELF-LIFE BIODEGRADABLE, BIOCOMPATIBLE MICROPARTICLES CONTAINING A BIOLOGICALLY ACTIVE AGENT

Owner: ALKERMES, INC. and JANSSEN PHARMACEUTICA

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	02	ORD	Granted	08/850,679	02-May-1997	5,792,477	11-Aug-1998	02-May-2017
US	03*	CON	Granted	09/071,865	04-May-1998	5,916,598	29-Jun-1999	02-May-2017
US	04*	CON	Granted	09/263,098	05-Mar-1999	6,110,503	29-Aug-2000	02-May-2017
US	05*	CON	Granted	09/578,717	26-May-2000	6,290,983	18-Sep-2001	02-May-2017
US	06*	CON	Granted	09/920,862	03-Aug-2001	6,403,114	11-Jun-2002	02-May-2017
US	11*	REX	Granted	90/007,587	15-Jun-2005	6,110,503	02-Feb-2010	02-May-2017
US	12	REX	Granted	90/008,093	26-Jun-2006	5,792,477	13-Jul-2010	02-May-2017

NOTE: The assignment in cases noted (*) denote Alkermes, Inc. ownership only. Other cases without note, including all ex-US patents and applications, are co-owned by Alkermes and Janssen Pharmaceutica.

Alkermes Patent Schedule

September 2011

Case #: 000166.0070

Title: METHOD FOR PREPARING MICROPARTICLES HAVING A SELECTED RELEASE PROFILE

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	01	ORD	Granted	09/223,276	30-Dec-1998	6,194,006	27-Feb-2001	30-Dec-2018
US	02	CON	Granted	09/722,335	28-Nov-2000	6,379,703	30-Apr-2002	30-Dec-2018
US	03	CON	Granted	10/059,115	31-Jan-2002	6,596,316	22-Jul-2003	30-Dec-2018

Alkermes Patent Schedule

September 2011

Case #: 000166.0073

Title: PREPARATION OF INJECTABLE SUSPENSIONS HAVING IMPROVED INJECTABILITY

Owner: ALKERMES PHARMA IRELAND LIMITED AND ALKERMES CONTROLLED THERAPEUTICS, INC.¹

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	00	ORD	Granted	09/577,875	25-May-2000	6,495,164	17-Dec-2002	25-May-2020
US	01	CON	Granted	10/259,949	30-Sep-2002	6,667,061	23-Dec-2003	25-May-2020
US	02	DIV	Granted	10/681,142	09-Oct-2003	7,371,406	13-May-2008	25-May-2020
US	03	CON	Granted	11/826,994	19-Jul-2007	7,799,345	21-Sep-2010	25-May-2020
US	05	CON	Published	12/856,198	13-Aug-2010			

Case #: 000166.0075

Title: APPARATUS AND METHOD FOR PREPARING MICROPARTICLES

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	00	ORD	Granted	09/438,659	12-Nov-1999	6,331,317	18-Dec-2001	12-Nov-2019
US	01	CON	Granted	09/828,849	10-Apr-2001	6,395,304	28-May-2002	12-Nov-2019
US	02	CON	Granted	10/109,641	01-Apr-2002	6,537,586	25-Mar-2003	12-Nov-2019
US	03	CON	Granted	10/355,061	31-Jan-2003	6,713,090	30-Mar-2004	12-Nov-2019
US	04	CON	Granted	10/713,039	17-Nov-2003	6,861,016	01-Mar-2005	12-Nov-2019

¹ Recordation in the relevant patent office(s) to reflect ownership interest held by Alkermes Pharma Ireland Limited will occur after Close.

Alkermes Patent Schedule

September 2011

Case #: 000166.0077

Title: PROCESS FOR ADJUSTING POLYMER MOLECULAR WEIGHT POLYMER MICROPARTICLES

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	00	ORD	Granted	09/575,075	19-May-2000	6,264,987	24-Jul-2001	19-May-2020
US	01	CON	Granted	09/870,751	01-Jun-2001	6,379,704	30-Apr-2002	19-May-2020
US	02	CON	Granted	10/073,864	14-Feb-2002	6,534,092	18-Mar-2003	19-May-2020
US	00	ORD	Granted	09/671,426	27-Sep-2000	6,471,995	29-Oct-2002	27-Sep-2020
US	01	DIV	Granted	10/235,534	06-Sep-2002	6,830,737	14-Dec-2004	27-Sep-2020
US	02	CON	Granted	10/821,941	12-Apr-2004	6,884,372	26-Apr-2005	27-Sep-2020

Case #: 000166.0098

Title: APPARATUS AND METHOD FOR PREPARING MICROPARTICLES USING IN-LINE SOLVENT EXTRACTION

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	00	ORD	Granted	09/438,656	12-Nov-1999	6,495,166	17-Dec-2002	12-Nov-2019
US	01	DIV	Granted	09/930,450	16-Aug-2001	6,540,393	01-Apr-2003	12-Nov-2019
US	02	CON	Granted	10/319,845	16-Dec-2002	6,705,757	16-Mar-2004	12-Nov-2019
US	03	CON	Granted	10/729,909	09-Dec-2003	6,939,033	06-Sep-2005	12-Nov-2019
US	04	CON	Granted	11/158,078	22-Jun-2005	7,300,671	27-Nov-2007	12-Nov-2019
US	05	CON	Granted	11/826,533	16-Jul-2007	7,510,730	31-Mar-2009	12-Nov-2019

Case #: 000166.0106

Title: ACID END GROUP POLY(D,L-LACTIDE-CO-GLYCOLIDE) COPOLYMERS WITH HIGH GLYCOLIDE CONTENT

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	00	ORD	Granted	09/635,677	10-Aug-2000	6,362,308	26-Mar-2002	10-Aug-2020
US	01	DIV	Granted	10/060,235	01-Feb-2002	6,703,477	09-Mar-2004	10-Aug-2020
US	02	CON	Granted	10/724,107	01-Dec-2003	7,074,883	11-Jul-2006	10-Aug-2020

Alkermes Patent Schedule

September 2011

Case #: 000166.0108

Title: METHOD FOR IMPROVING MICROSPHERE FLOWABILITY CHARACTERISTICS

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	01	CIP	Granted	10/022,859	20-Dec-2001	7,247,319	24-Jul-2007	26-Jan-2023

Case #: 000166.0112

Title: RESIDUAL SOLVENT EXTRACTION METHOD AND MICROPARTICLES PRODUCED THEREBY

Owner: ALKERMES PHARMA IRELAND LIMITED²

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	00	ORD	Granted	09/942,631	31-Aug-2001	6,824,822	30-Nov-2004	31-Aug-2021
US	02	CON	Granted	11/312,371	21-Dec-2005	7,223,440	29-May-2007	31-Aug-2021
US	03	CON	Granted	11/785,638	19-Apr-2007	7,524,530	28-Apr-2009	31-Aug-2021
US	06	CON	Granted	12/382,637	20-Mar-2009	7,875,310	25-Jan-2011	31-Aug-2021
US	07	CON	Published	12/967,757	14-Dec-2010			

Case #: 000166.0118

Title: CROSSLINKED HYDROGEL COPOLYMERS

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	00	ORD	Granted	10/273,365	18-Oct-2002	6,800,663	05-Oct-2004	18-Oct-2022

Case #: 000166.0119

Title: METHOD AND APPARATUS FOR FILTERING AND DRYING A PRODUCT

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	00	ORD	Granted	10/304,058	26-Nov-2002	7,089,681	15-Aug-2006	26-Nov-2022

² Recordation in the relevant patent office(s) to reflect ownership interest held by Alkermes Pharma Ireland Limited will occur after Close.

Alkermes Patent Schedule September 2011

Case #: 000166.0127

Title: COACERVATION PROCESS

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	1	ORD	Pending	12/051,395	19-Mar-2008			

Case #: 000166.0129

Title: QUENCH LIQUIDS AND WASHING SYSTEMS FOR PRODUCTION MICROPARTICLES

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US		ORD	Pending	12/140,542	17-Jun-2008			

Case #: 000166.0138

Title: INJECTABLE FORMULATION OF ENTECAVIR FOR TREATMENT OF HEPATITIS B

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US		PRO	Pending	61/529,705	31-Aug-2011			

Alkermes Patent Schedule

September 2011

Case #: 000166.2025

Title: MICROENCAPSULATION AND SUSTAINED RELEASE OF BIOLOGICALLY ACTIVE POLYPEPTIDES

Owner: ALKERMES PHARMA IRELAND LIMITED³

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	01	ORD	Granted	10/688,786	17-Oct-2003	7,164,005	16-Jan-2007	17-Oct-2023
US	02	ORD	Granted	10/688,059	17-Oct-2003	7,462,365	09-Dec-2008	06-Feb-2025
US	04	CON	Published	12/289,857	06-Nov-2008			

³ Recordation in the relevant patent office(s) to reflect ownership interest held by Alkermes Pharma Ireland Limited will occur after Close.

Alkermes Patent Schedule

September 2011

Case #: 000166.2056

Title: POLYMER-BASED SUSTAINED RELEASE DEVICE

Owner: ALKERMES PHARMA IRELAND LIMITED⁴ and AMYLIN PHARMACEUTICALS, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	01*	RCE	Granted	11/104,877	13-Apr-2005	7,456,254	25-Nov-2008	30-Jun-2025
US	03*	PCT	Pending	10/592,769	14-Sep-2006			15-Apr-2024
US	04	DIV	Granted	11/521,091	14-Sep-2006	7,563,871	21-Jul-2009	15-Apr-2024
US	09*	CON	Granted	11/826,535	16-Jul-2007	7,612,176	03-Nov-2009	13-Apr-2025
US	12	ORD	Published	11/578,712	23-Jan-2008			
US	14	CON	Published	12/483,871	12-Jun-2009			
US	15*	CON	Published	12/585,574	17-Sep-2009			
US	16*	CON	Published	12/713,036	25-Feb-2010			

NOTE: The assignment in cases noted (*) denote Alkermes, Inc. as the assignee. All other US cases are assigned to both Alkermes, Inc. and Amylin Pharmaceuticals, Inc.

⁴ Recordation in the relevant patent office(s) to reflect ownership interest held by Alkermes Pharma Ireland Limited will occur after Close.

Alkermes Patent Schedule

September 2011

Case #: 4000.3000

Title: Polymorphic Forms of Naltrexone

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	1	ORD	Granted	10/860,608	03-Jun-2004	7,279,579	09-Oct-2007	07-May-2026
US	2	DIV	Published	11/860,677	25-Sep-2007			

Case #: 4000.3002

Title: Methods for Administering Active Agent to CYP3A4 Sensitive Patients

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	1	ORD	Published	12/241,404	30-Sep-2008			

Case #: 4000.3003

Title: Aripiprazole, Olanzapine and Haloperidol Pamoate Salts

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US		ORD	Granted	10/635,232	06-Aug-2003	6,987,111	17-Jan-2006	10-May-2024

Alkermes Patent Schedule

September 2011

Case #: 4000.3005

Title: Methods for Administering Aripiprazole

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	1	CON	Pending	12/251,656	15-Oct-2008			

Alkermes Patent Schedule September 2011

Case #: 4000.3010

Title: Naltrexone Long Acting Formulations and Methods of Use

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	1	ORD	Granted	11/083,167	17-Mar-2005	7,919,499	05-Apr-2011	15-Oct-2029
US	2	DIV	Published	13/037,713	01-Mar-2011			

Alkermes Patent Schedule

September 2011

Case #: 4000.3022

Title: Selective Opioid Compounds

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	2	ORD	Published	12/371,334	13-Feb-2009			

Case #: 4000.3027

Title: Morphinan Derivatives with High Oral Bioavailability

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	1	ORD	Published	12/727,784	19-Mar-2010			

Case #: 4000.3028

Title: Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	2	ORD	Published	12/823,007	24-Jun-2010			

Alkermes Patent Schedule September 2011

Case #: 4000.3030

Title: Asenapine Prodrugs

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	1	ORD	Pending	12/978,298	23-Dec-2010			

Case #: 4000.3031

Title: Quaternary Ammonium Salt Prodrugs

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	1	ORD	Published	12/978,178	23-Dec-2010			

Alkermes Patent Schedule

September 2011

Case #: 4000.3033

Title: Prodrugs NH-Acidic Compounds

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	1A	ORD	Published	12/823,102	24-Jun-2010			

Case #: 4000.3034

Title: Prodrugs Heteraromatic Compounds

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	1	ORD	Pending	12/978,273	23-Dec-2010			

Case #: 4000.3035

Title: Prodrugs for the Treatment of Schizophrenia and Bipolar Disease

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	1	ORD	Published	12/978,274	23-Dec-2010			

Alkermes Patent Schedule

September 2011

Case #: 4000.3036

Title: Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	1	ORD	Published	12/978,240	23-Dec-2010			

Case #: 4000.3038

Title: Morphinan Derivatives for the Treatment of Drug Overdose

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	1	ORD	Published	12/903,462	13-Oct-2010			

Case #: 4000.3039

Title: Process for Synthesizing Oxidized Lactam Compounds

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	1	ORD	Pending	13/100,515	04-May-2011			

Alkermes Patent Schedule

September 2011

Case #: 4000.3041

Title: Process for the Synthesis Substituted Morphinans

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	1	ORD	Pending	13/096,679	28-Apr-2011			

Case #: 4000.3042

Title: Prodrugs NH-Acidic Compounds: Carbonate, Carbamate and Phosphonate Derivatives

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	1	ORD	Pending	13/168,497	24-Jun-2011			

Case #: 4000.3043

Title: Methods for Treating Antipsychotic-Induced Weight Gain

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	1	ORD	Pending	13/215,718	23-Aug-2011			23-Aug-2031

Case #: 4000.3044

Title: Multi-API Loading Prodrugs

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US		PRO	Pending	61/427,026	23-Dec-2010			23-Dec-2011

Alkermes Patent Schedule September 2011

Case #: 4000.3047

Title: Peripherally Acting Mu Opioid Antagonists

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US		PRO	Pending	61/442,629	14-Feb-2011			14-Feb-2012

Case #: 4000.3048

Title: Process for the Synthesis of Quaternary Amine Compounds

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US		PRO	Pending	61/472,016	05-Apr-2011			05-Apr-2012

Case #: 4000.3051

Title: Crystalline Salt Forms of an Opioid Modulator

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US		PRO	Pending	61/495,203	09-Jun-2011			09-Jun-2012

Alkermes Patent Schedule

September 2011

Case #: 4000.3052

Title: Peripherally Acting Opioid Compounds

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US		PRO	Pending	61/502,721	29-Jun-2011			

Case #: 4000.3054

Title: Prodrugs of Nucleoside Analogs

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US		PRO	Pending	61/527,986	26-Aug-2011			

Alkermes Patent Schedule September 2011

Case #: 513352

Title: Formulations Having Improved Site Reactions

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US		PRO	Pending	61/454,008	18-Mar-2011			18-Mar-2012

Alkermes Patent Schedule

September 2011

Case #: 1733.1002

Title: Composition for Sustained Release Human Growth Hormone

Owner: ALKERMES CONTROLLED THERAPEUTICS, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	4	CON	Granted	09/505,508	17-Feb-2000	6,500,448	31-Dec-2002	02-Dec-2012

Case #: 1733.1004

Title: Composition and Method for the Controlled Release Metal Cation-Stabilized Interferon

Owner: ALKERMES CONTROLLED THERAPEUTICS, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US		ORD	Granted	08/279,784	25-Jul-1994	5,711,968	27-Jan-1998	27-Jan-2015
US	001	CON	Granted	08/765,558	07-Mar-1997	6,165,508	26-Dec-2000	26-Dec-2017
US	014	CON	Granted	10/092,365	06-Mar-2002	6,780,434	24-Aug-2004	25-Jul-2014

Case #: 1733.1009

Title: Production Scale Method Forming Microparticles

Owner: ALKERMES CONTROLLED THERAPEUTICS, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US		ORD	Granted	08/443,726	18-May-1995	5,922,253	13-Jul-1999	13-Jul-2016
US	021	CON	Granted	09/305,413	05-May-1999	6,153,129	28-Nov-2000	18-May-2015
US	022	CON	Granted	09/587,821	06-Jun-2000	6,358,443	19-Mar-2002	18-May-2015
US	023	CON	Granted ⁵	10/006,991	06-Dec-2001	6,726,860	27-Apr-2004	13-Jul-2015
US	041	CON	Granted	10/784,474	23-Feb-2004	7,037,450	02-May-2006	06-Dec-2021

⁵ Note: The Company has decided to abandon this registration

Alkermes Patent Schedule

September 2011

Case #: 1733.1015

Title: Method for Fabricating Polymer-Based Controlled-Release Devices

Owner: ALKERMES CONTROLLED THERAPEUTICS, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US		ORD	Granted	08/649,128	14-May-1996	5,817,343	06-Oct-1998	14-May-2016
US	007	CIP	Granted	08/779,777	07-Jan-1997	6,183,781	06-Feb-2001	14-May-2016

Case #: 1733.1016

Title: Composition and Method Using Solid-Phase Particles for Sustained In Vivo Release a Biologically Active Agent

Owner: ALKERMES CONTROLLED THERAPEUTICS, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	001	ORD	Granted	08/705,197	29-Aug-1996	5,916,597	29-Jun-1999	29-Aug-2016

Case #: 1733.1018

Title: Device for the Sustained Release Aggregation-Stabilized Biologically Active Agent

Owner: ALKERMES CONTROLLED THERAPEUTICS, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	008	CON	Granted	08/934,830	22-Sep-1997	6,514,533	04-Feb-2003	31-Aug-2015
US	011	CON	Granted	09/820,587	29-Mar-2001	6,555,525	29-Apr-2003	31-Aug-2015

Case #: 1733.1044

Title: A Method for Purifying Human Growth Hormone

Owner: ALKERMES CONTROLLED THERAPEUTICS, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US		ORD	Granted	09/260,362	01-Mar-1999	6,451,347	17-Sep-2002	01-Mar-2019

Alkermes Patent Schedule

September 2011

Case #: 1733.1045

Title: Method for Producing Submicron Particles a Labile Agent and Use There

Owner: ALKERMES CONTROLLED THERAPEUTICS, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US		ORD	Granted	09/321,091	28-May-1999	6,444,223	03-Sep-2002	28-May-2019
US	007	CON	Granted	10/200,057	18-Jul-2002	6,713,087	30-Mar-2004	28-May-2019

Case #: 1733.1051

Title: Method for Producing Sub-Micron Particles Biologically Active Agents and Uses There

Owner: ALKERMES CONTROLLED THERAPEUTICS, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US		ORD	Granted	09/422,751	21-Oct-1999	6,284,283	04-Sep-2001	21-Oct-2019
US	003	CON	Granted	09/898,524	03-Jul-2001	6,428,815	06-Aug-2002	21-Oct-2019

Case #: 1733.1055

Title: Microencapsulation and Sustained Release Biologically Active Acid-Stable or Free Sulfhydryl-Containing Proteins

Owner: ALKERMES CONTROLLED THERAPEUTICS, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US		ORD	Granted	09/501,934	10-Feb-2000	6,465,425	15-Oct-2002	10-Feb-2020

Case #: 1733.1056

Title: Process for the Preparation of Polymer-Based Sustained Release Compositions

Owner: ALKERMES CONTROLLED THERAPEUTICS, INC. AND ALKERMES PHARMA IRELAND LIMITED⁶

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	001	CON	Granted	09/801,272	07-Mar-2001	6,479,065	12-Nov-2002	10-Aug-2020

⁶ Recordation in the relevant patent office(s) to reflect ownership interest held by Alkermes Pharma Ireland Limited will occur after Close.

Alkermes Patent Schedule

September 2011

Case #: 1733.1057

Title: Method and Apparatus for Uniform Sorbate Equilibration Solid Samples

Owner: ALKERMES CONTROLLED THERAPEUTICS, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US		ORD	Granted	09/507,238	18-Feb-2000	6,499,361	31-Dec-2002	18-Feb-2020

Case #: 1733.1062

Title: Methods and Compositions for the Targeted Delivery of Biologically Active Agents

Owner: ALKERMES CONTROLLED THERAPEUTICS, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	003	CON	Granted	10/342,448	14-Jan-2003	7,097,857	29-Aug-2006	20-Mar-2021

Case #: 1733.1068

Title: Method of Modifying the Release Profile Sustained Release Compositions

Owner: ALKERMES CONTROLLED THERAPEUTICS, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	008	CON	Granted	10/758,717	16-Jan-2004	7,074,432	11-Jul-2006	25-Mar-2023

Case #: 1733.1070

Title: Process for Producing Small Particles Biologically Active Molecules

Owner: ALKERMES CONTROLLED THERAPEUTICS, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	017	FWC	Granted	08/006,682	21-Jan-1993	6,569,458	27-May-2003	27-May-2020

Alkermes Patent Schedule September 2011

Case #: 1733.2012

Title: Method of Preparing Sustained Release Microparticles

Owner: ALKERMES CONTROLLED THERAPEUTICS, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US	001	ORD	Granted	10/762,220	21-Jan-2004	7,658,998	09-Feb-2010	13-Oct-2027

Case #: 1733.2040

Title: Method of Modifying the Release Profile Sustained Release Compositions

Owner: ALKERMES CONTROLLED THERAPEUTICS, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US		CON	Pending ⁷	11/826,694	17-July-2007			

Case #: 0947.1044-031

Title: Increasing Blood-Brain Barrier Permeability with Permeabilizer Peptides

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
US		DIV	Granted	08/121,058	13-Sep-1993	5,506,206	09-Apr-1996	09-Apr-2013

⁷ Note: The Company has decided to abandon this application

Country	Status	Patent Number	Application Number	Publication Number	Filing Date	Issue / Grant Date	Normal Expiry Date	Owner	Short Title / Subject Matter
USA	Granted	5260478	07/966,646		08-Dec-1992	09-Nov-1996	08-Dec-2012	Alkermes Pharma Ireland Limited	IODINATED AROY_OXY CARBOXYAMIDES
USA	Granted	5264610	08/038,371		29-Mar-1993	23-Nov-1996	29-Mar-2013	Alkermes Pharma Ireland Limited	IODINATED AROMATIC PROPANEDIATES
USA	Granted	5329404	08/148,112		04-Nov-1992	12-Jul-1994	29-Mar-2013	Alkermes Pharma Ireland Limited	METHOD OF X-RAY IMAGING USING IODINATED AROMATIC PROPANEDIATES
USA	Granted	5299262	07/987,504		04-Dec-1992	29-Mar-1994	04-Dec-2012	Alkermes Pharma Ireland Limited	USE OF IONIC CLOUD POINT MODIFIERS TO PREVENT PARTICLE AGGREGATION DURING STERILIZATION
USA	Granted	5302401	07/987,879		09-Dec-1992	12-Apr-1994	09-Dec-2012	Alkermes Pharma Ireland Limited	METHOD TO REDUCE PARTICLE SIZE GROWTH DURING X-OPHILIZATION
USA	Granted	5451539	08/207,538		07-Mar-1994	19-Sep-1995	19-Sep-2012	Alkermes Pharma Ireland Limited	X RAY CONTRAST COMPOSITIONS USEFUL IN MEDICAL IMAGING
USA	Granted	5322679	07/990,587		18-Dec-1992	21-Jun-1994	18-Dec-2012	Alkermes Pharma Ireland Limited	IODINATED AROY_OXY ESTERS
USA	Granted	5469438	08/261,794		20-Jun-1994	14-Nov-1996	18-Dec-2012	Alkermes Pharma Ireland Limited	IODINATED AROY_OXY ESTERS
USA	Granted	5329552	07/991,509		17-Dec-1992	05-Jul-1994	17-Dec-2012	Alkermes Pharma Ireland Limited	FORMULATIONS FOR NANOPARTICULATE X-RAY BLOOD POOL CONTRAST AGENTS USING HIGH
USA	Granted	5447710	08/242,492		13-May-1994	05-Sep-1996	05-Sep-2012	Alkermes Pharma Ireland Limited	METHOD OF MAKING NANOPARTICULATE X-RAY BLOOD POOL CONTRAST AGENTS USING HIGH
USA	Granted	5330739	07/985,415		04-Dec-1992	19-Jul-1994	04-Dec-2012	Alkermes Pharma Ireland Limited	IODINATED BENZOYL ACETALS AND KETALS FOR X-RAY IMAGING
USA	Granted	5470583	08/240,508		10-May-1994	26-Nov-1996	11-Dec-2012	Alkermes Pharma Ireland Limited	METHOD OF PREPARING NANOPARTICLE COMPOSITIONS CONTAINING CHARGED PHOSPHOLIPIDS TO
USA	Granted	5349688	07/991,640				16-Dec-2012	Alkermes Pharma Ireland Limited	NCD - Diagnostic Imaging
USA	Granted	5349702	07/985,424		04-Dec-1992	13-Sep-1994	04-Dec-2012	Alkermes Pharma Ireland Limited	USE OF NON-IONIC CLOUD POINT MODIFIERS TO MINIMIZE NANOPARTICLE AGGREGATION DURING
USA	Granted	5362459	07/991,636		16-Dec-1992	04-Oct-1994	16-Dec-2012	Alkermes Pharma Ireland Limited	USE OF PURIFIED SURFACE MODIFIERS TO PREVENT PARTICLE AGGREGATION DURING STERILIZATION
USA	Granted	5384107	08/285,956		03-Aug-1994	24-Jan-1995	14-Dec-2012	Alkermes Pharma Ireland Limited	IODINATED AROMATIC COMPOUNDS
USA	Granted	5494683	08/365,267		29-Dec-1994	27-Feb-1996	27-Feb-2013	Alkermes Pharma Ireland Limited	SURFACE MODIFIED ANTICANCER NANOPARTICLES
USA	Granted	5401432	07/981,636		17-Dec-1992	26-Mar-1995	17-Dec-2012	Alkermes Pharma Ireland Limited	WATER INSOLUBLE NON-MAGNETIC MANGANESE PARTICLES AS MAGNETIC RESONANCE CONTRAST
USA	Granted	5429824	07/980,874		15-Dec-1992	04-Jul-1995	15-Dec-2012	Alkermes Pharma Ireland Limited	USE OF TY_OXAPOL AS A NANOPARTICLE STABILIZER AND DISPERSANT
USA	Granted	5468440	08/367,407		30-Dec-1994	14-Nov-1996	30-Dec-2014	Alkermes Pharma Ireland Limited	FORMULATIONS OF ORAL GASTROINTESTINAL DIAGNOSTIC X-RAY CONTRAST AGENTS IN COMBINATION
USA	Granted	5643552	08/624,145		22-Aug-1995	01-Jul-1997	22-Aug-2015	Alkermes Pharma Ireland Limited	NANOPARTICULATE DIAGNOSTIC MIXED CARBONIC ANHYDRIDES AS X-RAY CONTRAST AGENTS FOR
USA	Granted	5472683	08/401,570		09-Mar-1995	05-Dec-1996	09-Mar-2015	Alkermes Pharma Ireland Limited	NANOPARTICULATE DIAGNOSTIC MIXED CARBAMIC ANHYDRIDES AS X-RAY CONTRAST AGENTS FOR
USA	Granted	5573749	08/401,597		09-Mar-1995	12-Nov-1996	09-Mar-2015	Alkermes Pharma Ireland Limited	NANOPARTICULATE DIAGNOSTIC MIXED CARBOXYLIC ANHYDRIDES AS X-RAY CONTRAST AGENTS FOR
USA	Granted	5488133	08/209,181		10-Mar-1994	30-Jan-1996	10-Mar-2014	Alkermes Pharma Ireland Limited	IODINATED AROY_OXY KETONES
USA	Granted	5500204	08/366,788		10-Feb-1995	19-Mar-1996	10-Feb-2015	Alkermes Pharma Ireland Limited	NANOPARTICULATE DIAGNOSTIC DIMERS AS X-RAY CONTRAST AGENTS FOR BLOOD POOL AND
USA	Granted	5503728	08/365,531		08-Feb-1995	02-Apr-1996	08-Feb-2015	Alkermes Pharma Ireland Limited	ISOLATION OF ULTRA SMALL PARTICLES
USA	Granted	5510118	08/368,192		14-Feb-1995	23-Apr-1996	14-Feb-2015	Alkermes Pharma Ireland Limited	PROCESS OF PREPARING THERAPEUTIC COMPOSITIONS CONTAINING NANOPARTICLES
USA	Granted	5518187	08/180,827		12-Jan-1994	21-May-1996	12-Jan-2014	Alkermes Pharma Ireland Limited	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
USA	Granted	5518738	08/365,614		09-Feb-1995	21-May-1996	09-Feb-2015	Alkermes Pharma Ireland Limited	NANOPARTICULATE NSAD COMPOSITIONS
USA	Granted	5521218	08/440,794		15-May-1995	28-May-1996	15-May-2015	Alkermes Pharma Ireland Limited	NANOPARTICULATE IODIPAMIDE DERIVATIVES FOR USE AS X-RAY CONTRAST AGENTS
USA	Granted	5525228	08/265,550		24-Jun-1994	11-Jun-1996	24-Jun-2014	Alkermes Pharma Ireland Limited	NANOPARTICULATE DIAGNOSTIC DIACETOXY ESTER X-RAY CONTRAST AGENTS FOR BLOOD POOL AND
USA	Granted	5534270	08/366,028		09-Feb-1995	09-Jul-1996	09-Feb-2015	Alkermes Pharma Ireland Limited	METHOD OF PREPARING STABLE DRUG NANOPARTICLES
USA	Granted	5543133	08/368,099		14-Feb-1995	06-Aug-1996	14-Feb-2015	Alkermes Pharma Ireland Limited	PROCESS OF PREPARING X-RAY CONTRAST COMPOSITIONS CONTAINING NANOPARTICLES
USA	Granted	5571538	08/384,057		06-Feb-1995	05-Nov-1996	06-Feb-2015	Alkermes Pharma Ireland Limited	FORMULATIONS OF COMPOUNDS AS NANOPARTICULATE DISPERSIONS IN DIGESTIBLE OILS OR FATTY
USA	Granted	5560931	08/368,088		14-Feb-1995	01-Oct-1996	14-Feb-2015	Alkermes Pharma Ireland Limited	FORMULATIONS OF COMPOUNDS AS NANOPARTICULATE DISPERSIONS IN DIGESTIBLE OILS OR FATTY
USA	Granted	5560932	08/370,555		10-Jan-1995	01-Oct-1996	10-Jan-2015	Alkermes Pharma Ireland Limited	MICROPRECIPITATION OF NANOPARTICULATE PHARMACEUTICAL AGENTS
USA	Granted	5565188	08/365,872		24-Feb-1995	15-Oct-1996	24-Feb-2015	Alkermes Pharma Ireland Limited	POLYALKYLENE BLOCK COPOLYMERS AS SURFACE MODIFIERS FOR NANOPARTICLES
USA	Granted	5705194	08/727,868		08-Oct-1998	06-Jan-1999	24-Feb-2015	Alkermes Pharma Ireland Limited	POLYALKYLENE BLOCK COPOLYMERS AS SURFACE MODIFIERS FOR NANOPARTICLES
USA	Granted	5569448	08/370,022		24-Jan-1995	29-Oct-1996	24-Jan-2015	Alkermes Pharma Ireland Limited	SULFATED NONIONIC BLOCK COPOLYMER SURFACTANTS AS STABILIZER COATINGS FOR NANOPARTICLE
USA	Granted	5573750	08/447,133		22-May-1996	12-Nov-1996	22-May-2015	Alkermes Pharma Ireland Limited	DIAGNOSTIC IMAGING X-RAY CONTRAST AGENTS
USA	Granted	5573783	08/387,851		13-Feb-1995	12-Nov-1996	13-Feb-2015	Alkermes Pharma Ireland Limited	REDISPERSIBLE NANOPARTICULATE FILM MATRICES WITH PROTECTIVE OVERCOATS
USA	Granted	5580679	08/388,678		15-Feb-1995	09-Dec-1996	15-Feb-2015	Alkermes Pharma Ireland Limited	SITE-SPECIFIC ADHESION WITHIN THE GI TRACT USING NANOPARTICLES STABILIZED BY HIGH
USA	Granted	5585108	08/368,518		30-Dec-1994	17-Dec-1996	30-Dec-2014	Alkermes Pharma Ireland Limited	FORMULATIONS OF ORAL GASTROINTESTINAL THERAPEUTIC AGENTS IN COMBINATION WITH
USA	Granted	5587143	08/267,082		28-Jun-1994	24-Dec-1996	28-Jun-2014	Alkermes Pharma Ireland Limited	BUTYLENE OXIDE-ETHYLENE OXIDE BLOCK COPOLYMER SURFACTANTS AS STABILIZER COATINGS FOR
USA	GRANTED	5591456	08/368,790		10-Feb-1995	07-Jan-1997	10-Feb-2015	Alkermes Pharma Ireland Limited	MILLED NAPROXEN WITH HYDROXYPROPYLCELLULOSE AS A DISPERSION STABILIZER
USA	Granted	5593657	08/368,027		09-Feb-1995	14-Jan-1997	09-Feb-2015	Alkermes Pharma Ireland Limited	NOVEL BARIUM SALT FORMULATIONS STABILIZED BY NON-IONIC AND ANIONIC STABILIZERS
USA	Granted	5603916	08/447,132		22-May-1995	18-Feb-1997	22-May-2015	Alkermes Pharma Ireland Limited	3,5-BIS(4-ARYLOXYAMINO-2,4,6-TRIMETHYLBENZYL) ESTERS
USA	Granted	5622938	08/444,796		19-May-1995	22-Apr-1997	09-Feb-2015	Alkermes Pharma Ireland Limited	SUGAR BASE SURFACTANT FOR NANOCRYSTALS
USA	Granted	5628981	08/366,841		30-Dec-1994	13-May-1997	30-Dec-2014	Alkermes Pharma Ireland Limited	FORMULATIONS OF ORAL GASTROINTESTINAL DIAGNOSTIC X-RAY CONTRAST AGENTS AND ORAL
USA	Granted	6,432,381 B2	08/815,346	US 2001-0006917 A1	11-Mar-1997	13-Aug-2002	30-Dec-2014	Alkermes Pharma Ireland Limited	METHODS FOR TARGETING DRUG DELIVERY TO THE UPPER AND/OR LOWER GASTROINTESTINAL TRACT
USA	Published		10,175,851	US 2003-0064045 A1	21-Jan-2002		30-Dec-2014	Alkermes Pharma Ireland Limited	METHODS FOR TARGETING DRUG DELIVERY TO THE UPPER AND/OR LOWER GASTROINTESTINAL TRACT
USA	Granted	5662683	08/370,536		10-Jan-1995	02-Sep-1997	10-Jan-2015	Alkermes Pharma Ireland Limited	MICROPRECIPITATION OF MICRO-NANOPARTICULATE PHARMACEUTICAL AGENTS
USA	Granted	5665331	08/370,598		10-Jan-1995	09-Sep-1997	10-Jan-2015	Alkermes Pharma Ireland Limited	CO-MICROPRECIPITATION OF NANOPARTICULATE PHARMACEUTICAL AGENTS WITH CRYSTAL GROWTH
USA	Granted	5668196	08/477,709		10-Jul-1996	16-Sep-1997	10-Jul-2016	Alkermes Pharma Ireland Limited	NOVEL 3-AMINO-TRIDOPHENYL ESTERS AS X-RAY CONTRAST AGENTS
USA	Granted	5670138	08/468,363		16-Jan-1996	23-Sep-1997	23-Sep-2014	Alkermes Pharma Ireland Limited	2,4,6-TRIMETHOXY-5-SUBSTITUTED AMINOISOPHTHALATE ESTERS USEFUL AS X-RAY CONTRAST AGENTS FOR
USA	GRANTED	5719642	08/370,528		10-Jan-1995	10-Feb-1998	10-Feb-2015	Alkermes Pharma Ireland Limited	MICROPRECIPITATION OF NANOPARTICULATE PHARMACEUTICAL AGENTS USING SURFACE ACTIVE
USA	GRANTED	5719588	08/249,787		23-May-1994	17-Feb-1998	17-Feb-2015	Alkermes Pharma Ireland Limited	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
USA	Granted	5719619	08/393,848		23-May-1994	17-Feb-1998	17-Feb-2015	Alkermes Pharma Ireland Limited	NANOPARTICLES CONTAINING THE R(1)ENANTIOMER OF BUPROFEN
USA	Granted	5747001	08/393,873		24-Feb-1995	05-May-1998	05-May-2015	Alkermes Pharma Ireland Limited	AEROSOLS CONTAINING BECLOMETHAZONE NANOPARTICLE DISPERSIONS
USA	Granted	5834025	08/686,754		14-Aug-1996	10-Nov-1998	14-Aug-2016	Alkermes Pharma Ireland Limited	REDUCTION OF INTRAVENOUSLY ADMINISTERED NANOPARTICULATE FORMULATION-INDUCED ADVERSE
USA	Granted	HE41,884 E	12/027,100		06-Feb-2008	26-Oct-2010	14-Aug-2016	Alkermes Pharma Ireland Limited	REDUCTION OF INTRAVENOUSLY ADMINISTERED NANOPARTICULATE FORMULATION-INDUCED ADVERSE
USA	Granted	5862999	08/481,538		15-Jun-1995	26-Jan-1999	25-May-2014	Alkermes Pharma Ireland Limited	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
USA	Granted	5939030	08/836,819		14-Aug-1997	10-Aug-1999	10-Aug-2016	Alkermes Pharma Ireland Limited	POLYETHER COPOLYMERS AND A PROCESS FOR PREPARING THEM
USA	GRANTED	6043828	09/880,602		09-Jul-1997	04-Apr-2000	13-Feb-2017	Alkermes Pharma Ireland Limited	NANOCRYSTALLINE FORMULATIONS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITORS
USA	Granted	6063858	09/225,498		06-Jan-1999	30-May-2000	09-Jul-2017	Alkermes Pharma Ireland Limited	METHODS OF MAKING NANOCRYSTALLINE FORMULATIONS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV)
USA	Granted	6221400	09/225,498		06-Jan-1999	24-Apr-2001	13-Feb-2017	Alkermes Pharma Ireland Limited	METHODS OF TREATING MAMMALS USING NANOCRYSTALLINE FORMULATIONS OF HUMAN
USA	GRANTED	6153225	09/154,422		13-Aug-1998	28-Nov-2000	13-Aug-2018	Alkermes Pharma Ireland Limited	INJECTABLE FORMULATIONS OF NANOPARTICULATE NAPROXEN
USA	Granted	6163006	09/148,332		04-Sep-1998	26-Dec-2000	04-Sep-2018	Alkermes Pharma Ireland Limited	NEW SOLID DOSE FORM OF NANOPARTICULATE NAPROXEN
USA	Granted	6264922	08/948,216		09-Oct-1997	24-Jul-2001	24-Feb-2015	Alkermes Pharma Ireland Limited	NEBULIZED AEROSOLS CONTAINING NANOPARTICULATE DISPERSIONS
USA	Pending		09/777,489		22-May-2000		24-Feb-2015	Alkermes Pharma Ireland Limited	METHODS OF ADMINISTERING LIQUID DROPLET AEROSOLS OF NANOPARTICULATE DRUGS
USA	APPEAL		12/061,670	US 2008/027404 A1	18-Apr-2008		24-Feb-2015	Alkermes Pharma Ireland Limited	METHODS OF ADMINISTERING LIQUID DROPLET AEROSOLS OF NANOPARTICULATE DRUGS
USA	Granted	7,521,098 B2	09/190,138	US 2002-0102294 A1	12-Nov-1996	21-Apr-2009	12-Apr-2022	Alkermes Pharma Ireland Limited	DRY POWDER AEROSOLS OF NANOPARTICULATE DRUGS
USA	Granted	6811767	09/587,738		19-Jun-2000	02-Nov-2004	12-Nov-2018	Alkermes Pharma Ireland Limited	LIQUID DROPLET AEROSOLS OF NANOPARTICULATE DRUGS
USA	Published		12/820,431	US 2009-0181100 A1	26-Jan-2009		12-Nov-2018	Alkermes Pharma Ireland Limited	LIQUID DROPLET AEROSOLS OF NANOPARTICULATE DRUGS
USA	GRANTED	6270606	09/261,151		03-Mar-1998	07-Aug-2001	03-Mar-2019	Alkermes Pharma Ireland Limited	USE OF PEG-DERIVATIZED LIPIDS AS SURFACE STABILIZERS FOR NANOPARTICULATE COMPOSITIONS
USA	GRANTED	6267989	09/263,834		08-Mar-1998	31-Jul-2001	08-Mar-2019	Alkermes Pharma Ireland Limited	METHODS FOR PREVENTING CRYSTAL GROWTH AND PARTICLE AGGREGATION IN NANOPARTICULATE
USA	Granted	6865604	09/382,557		09-Sep-1999	02-Dec-2003	06-Sep-2019	Alkermes Pharma Ireland Limited	NANOPARTICULATE COMPOSITIONS COMPRISING AMORPHOUS CYCLOSPRINE AND METHODS OF
USA	Published		09/337,675	US 2002/0012675 A1	22-Jun-1999		01-Oct-2018	Alkermes Pharma Ireland Limited	CONTROLLED RELEASE NANOPARTICULATE COMPOSITIONS
USA	APPEAL		11/979,231	US 2008/0124393 A1	31-Oct-2007		01-Oct-2018	Alkermes Pharma Ireland Limited	CONTROLLED RELEASE NANOPARTICULATE CLOZAPINE COMPOSITIONS
USA	Published		12/483,188	US 2009/0297619 A1	11-Jun-2009		22-Jun-2019	Alkermes Pharma Ireland Limited	NANOPARTICULATE ANTICONVULSANT AND IMMUNOSUPPRESSIVE COMPOSITIONS

Country	Status	Patent Number	Application Number	Publication Number	Filing Date	Issue / Grant Date	Normal Expiry Date	Owner	Short Title / Subject Matter
USA	Pending		13/102,796		06-May-2001		01-Oct-2018	Alkermes Pharma Ireland Limited	CONTROLLED-RELEASE NANOPARTICULATE CLOZAPINE COMPOSITIONS
USA	Granted	6428614	09/414,159	US 2002-0068092 A1	06-Oct-1999	06-Aug-2002	09-Oct-2019	Alkermes Pharma Ireland Limited	BIOADHESIVE NANOPARTICULATE COMPOSITIONS HAVING CATIONIC SURFACE STABILIZERS
USA	Granted	7283267	10/404,808	US 2003-0103611 A1	06-Oct-1999	30-Oct-2007	23-May-2021	Alkermes Pharma Ireland Limited	BIOADHESIVE NANOPARTICULATE COMPOSITIONS HAVING CATIONIC SURFACE STABILIZERS
USA	Granted	7350936	11/858,274	US 2006-0003295 A1	11-Sep-2007	14-Dec-2010	09-Oct-2019	Alkermes Pharma Ireland Limited	BIOADHESIVE NANOPARTICULATE COMPOSITIONS HAVING CATIONIC SURFACE STABILIZERS
USA	Granted	6431478	09/583,893		31-May-2000	13-Aug-2002	26-Jul-2020	Alkermes Pharma Ireland Limited	SMALL-SCALE MILL AND METHOD THEREOF
USA	Granted	6743662	10/937,566	US 2002-0143062 A1	19-Oct-2001	08-Jun-2004	31-May-2020	Alkermes Pharma Ireland Limited	SMALL-SCALE MILL AND METHOD THEREOF
USA	Granted	6991191	10/833,045	US 2004-0251332 A1	28-Apr-2004	31-Jan-2008	30-Jun-2020	Alkermes Pharma Ireland Limited	SMALL-SCALE MILL AND METHOD THEREOF
USA	Granted	6319029	09/572,961		18-May-2000	13-Nov-2001	18-May-2020	Alkermes Pharma Ireland Limited	RAPIDLY DISINTEGRATING SOLID ORAL DOSAGE FORM
USA	Published		10/867,470	US 2004-0057993 A1	23-Sep-2003		18-May-2020	Alkermes Pharma Ireland Limited	RAPIDLY DISINTEGRATING SOLID ORAL DOSAGE FORM
USA	Published		12/068,706	US 2006-0213371 A1	11-Feb-2008		18-May-2020	Alkermes Pharma Ireland Limited	RAPIDLY DISINTEGRATING SOLID ORAL DOSAGE FORM
USA	Granted	6375686	09/666,539		21-Sep-2000	23-Apr-2002	21-Sep-2020	Alkermes Pharma Ireland Limited	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A
USA	Granted	6592903	10/475,443	US 2002-0110597 A1	15-Feb-2002	15-Jul-2005	21-Sep-2020	Alkermes Pharma Ireland Limited	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A
USA	Granted	6969529	10/345,312	US 2003-0103616 A1	16-Jan-2003	28-Nov-2005	21-Sep-2020	Alkermes Pharma Ireland Limited	NANOPARTICULATE COMPOSITIONS COMPRISING COPOLYMERS OF VINYL PYRROLIDONE AND VINYL
USA	Granted	7244451	11/213,785	US 2007-0141159 A1	30-Aug-2005	17-Jul-2007	06-Feb-2021	Alkermes Pharma Ireland Limited	METHODS OF MAKING NANOPARTICULATE DRUG COMPOSITIONS COMPRISING COPOLYMERS OF VINYL
USA	Granted	6582285	09/842,619	US 2001-0053654 A1	26-Apr-2001	24-Jun-2003	25-Apr-2021	Alkermes Pharma Ireland Limited	APPARATUS FOR SANITARY WET MILLING
USA	APPEAL		10/246,751	US 2003-0095828 A1	19-Sep-2002		19-Sep-2022	Alkermes Pharma Ireland Limited	NANOPARTICULATE COMPOSITIONS OF INSULIN
USA	Granted	6742734	10/162,933	US 2002-0179758 A1	04-Jun-2002	01-Jun-2004	06-Aug-2022	Alkermes Pharma Ireland Limited	SYSTEM AND METHOD FOR MILLING MATERIALS
USA	Granted	6979647	10/732,801	US 2004-0164194 A1	11-Dec-2003	20-Dec-2005	04-Jun-2022	Alkermes Pharma Ireland Limited	SYSTEM AND METHOD FOR MILLING MATERIALS
USA	Granted	7575184	11/833,645	US 2006-0026807 A1	03-Aug-2004	04-Aug-2022	04-Aug-2022	Alkermes Pharma Ireland Limited	SYSTEM AND METHOD FOR MILLING MATERIALS
USA	APPEAL		09/952,032	US 2006-0054042 A1	14-Sep-2001		14-Sep-2021	Alkermes Pharma Ireland Limited	STABILIZATION OF CHEMICAL COMPOUNDS USING NANOPARTICULATE FORMULATIONS
USA	APPEAL		11/602,158	US 2007-0224279 A1	21-May-2007		14-Sep-2021	Alkermes Pharma Ireland Limited	STABILIZATION OF CHEMICAL COMPOUNDS USING NANOPARTICULATE FORMULATIONS
USA	Pending		11/979,251		31-Oct-2007		14-Sep-2021	Alkermes Pharma Ireland Limited	STABILIZATION OF CHEMICAL COMPOUNDS USING NANOPARTICULATE FORMULATIONS
USA	Published		12/121,443	US 2009-0175951 A1	15-May-2008		14-Sep-2021	Alkermes Pharma Ireland Limited	NANOPARTICULATE COMPOSITIONS OF IMMUNOSUPPRESSIVE AGENTS
USA	Granted	7459283	10/357,514	US 2003-0185688 A1	04-Feb-2003	02-Dec-2006	10-Jul-2026	Alkermes Pharma Ireland Limited	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
USA	Published		12/292,091	US 2009-0074875 A1	12-Nov-2006		04-Feb-2023	Alkermes Pharma Ireland Limited	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
USA	APPEAL		11/275,089	US 2006-0193920 A1	07-Dec-2005		21-Sep-2020	Alkermes Pharma Ireland Limited	NANOPARTICULATE COMPOSITIONS OF MAP KINASE INHIBITORS
USA	APPEAL		10/635,324	US 2003-0129242 A1	04-Jan-2002		04-Jan-2022	Alkermes Pharma Ireland Limited	STERILE FILTERED NANOPARTICULATE FORMULATIONS OF BUDESONIDE AND BECLOMETHASONE
USA	Granted	7713551	10/659,706	US 2006-0091691 A1	11-Sep-2003	11-May-2010	12-Nov-2024	Alkermes Pharma Ireland Limited	GEL STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
USA	APPEAL		11/928,250	US 2006-0054061 A1	30-Oct-2007		20-Mar-2023	Alkermes Pharma Ireland Limited	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
USA	APPEAL		11/928,278	US 2006-0107741 A1	30-Oct-2007		20-Mar-2023	Alkermes Pharma Ireland Limited	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
USA	APPEAL		11/928,289	US 2006-0228732 A1	30-Oct-2007		20-Mar-2023	Alkermes Pharma Ireland Limited	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
USA	Published		12/076,247	US 2006-0220075 A1	14-Mar-2008		20-Mar-2023	Alkermes Pharma Ireland Limited	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
USA	Published		12/117,982	US 2006-0279849 A1	09-May-2008		20-Mar-2023	Alkermes Pharma Ireland Limited	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
USA	Published		12/670,722	US 2010-0322652 A1	27-Aug-2010		20-Mar-2023	Alkermes Pharma Ireland Limited	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
USA	Published		12/670,745	US 2010-0322653	27-Aug-2010		20-Mar-2023	Alkermes Pharma Ireland Limited	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
USA	Published		12/670,749	US 2010-0329876 A1	27-Aug-2010		20-Mar-2023	Alkermes Pharma Ireland Limited	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
USA	Granted	7101576	10/412,688	US 2003-0219490 A1	14-Apr-2003	05-Sep-2006	12-Apr-2024	Alkermes Pharma Ireland Limited	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
USA	Published		10/678,623	US 2005-0083077 A1	29-Jun-2004		14-Apr-2023	Alkermes Pharma Ireland Limited	NANOPARTICULATE MEGESTROL FORMULATIONS
USA	APPEAL		11/093,149	US 2005-0233001 A1	30-Mar-2005		14-Apr-2023	Alkermes Pharma Ireland Limited	NANOPARTICULATE MEGESTROL FORMULATIONS
USA	APPEAL		11/472,558	US 2010-0228989 A1	22-Jun-2009		20-Mar-2023	Alkermes Pharma Ireland Limited	NANOPARTICULATE MEGESTROL FORMULATIONS
USA	Published		12/826,557	US 2010-0266705 A1	29-Jun-2010		14-Apr-2023	Alkermes Pharma Ireland Limited	NANOPARTICULATE MEGESTROL FORMULATIONS
USA	Granted	7278249	10/444,066	US 2006-0278874 A1	23-May-2003	02-Oct-2007	21-Feb-2023	Alkermes Pharma Ireland Limited	NANOPARTICULATE FIBRATE FORMULATIONS
USA	Granted	7320802	10/692,855	US 2004-0058096 A1	27-Oct-2003	22-Jan-2008	21-Feb-2023	Alkermes Pharma Ireland Limited	METHODS OF TREATMENT USING NANOPARTICULATE FENOFIBRATE COMPOSITIONS
USA	APPEAL		11/710,607	US 2007-0264348 A1	26-Feb-2007		21-Feb-2023	Alkermes Pharma Ireland Limited	NANOPARTICULATE FIBRATE FORMULATIONS
USA	Allowed		11/802,542	US 2007-0259115 A1	23-May-2007		21-Feb-2023	Alkermes Pharma Ireland Limited	NANOPARTICULATE FIBRATE FORMULATIONS
USA	APPEAL		11/802,567	US 2006-0065651 A1	23-May-2007		21-Feb-2023	Alkermes Pharma Ireland Limited	NANOPARTICULATE FIBRATE FORMULATIONS
USA	Published		11/979,230	US 2006-0193424 A1	31-Oct-2007		21-Feb-2023	APL & Fournier	NANOPARTICULATE FIBRATE FORMULATIONS
USA	Published		12/058,497	US 2006-0241070 A1	28-Mar-2008		21-Feb-2023	APL & Fournier	NANOPARTICULATE FIBRATE FORMULATIONS
USA	Published		11/367,716	US 2011-0027371 A1	06-Mar-2006		01-Oct-2018	Alkermes Pharma Ireland Limited	NANOPARTICULATE STATIN FORMULATIONS & NOVEL STATIN COMBINATIONS
USA	Granted	7,783,278 B2	10/457,811	US 2003-0232796 A1	10-Jun-2003	27-Jul-2010	05-Mar-2024	Alkermes Pharma Ireland Limited	NANOPARTICULATE POLYCOSANOL FORMULATIONS AND NOVEL POLYCOSANOL COMBINATIONS
USA	Published		12/704,426	US 2010-0143682 A1	11-Feb-2010		10-Jun-2022	Alkermes Pharma Ireland Limited	NANOPARTICULATE POLYCOSANOL FORMULATIONS AND NOVEL POLYCOSANOL COMBINATIONS
USA	PENDING		10/784,500	US 2004-0223038 A1	24-Feb-2004		24-Feb-2024	Alkermes Pharma Ireland Limited	NANOPARTICULATE MELOXICAM FORMULATIONS
USA	Published		12/788,203	US 2010-0297252 A1	29-May-2010		24-Feb-2024	Alkermes Pharma Ireland Limited	NANOPARTICULATE MELOXICAM FORMULATIONS
USA	Published		10/705,227	US 2004-0158985 A1	12-Nov-2003		12-Nov-2023	Alkermes Pharma Ireland Limited	SOLID DOSAGE FORMS COMPRISING PULLULAN
USA	APPEAL		10/619,539	US 2004-0258757 A1	16-Jul-2003		16-Jul-2023	Alkermes Pharma Ireland Limited	LIQUID DOSAGE COMPOSITIONS OF STABLE NANOPARTICULATE ACTIVE AGENTS
USA	Pending		10/644,450		09-Mar-2011			Alkermes Pharma Ireland Limited	LIQUID DOSAGE COMPOSITIONS OF STABLE NANOPARTICULATE ACTIVE AGENTS
USA	APPEAL		10/654,600	US 2004-0105778 A1	04-Sep-2003		04-Sep-2023	Alkermes Pharma Ireland Limited	GAMMA IRRADIATION OF SOLID NANOPARTICULATE ACTIVE AGENTS
USA	Granted	7,190,795 B2	10/323,736	US 2004-0029096 A1	20-Dec-2002	03-Apr-2007	07-Jan-2021	Alkermes Pharma Ireland Limited	IN VITRO METHODS FOR EVALUATING THE IN VIVO EFFECTIVENESS OF DOSAGE FORMS OF
USA	Granted	7959739	11/650,412		06-Jan-2007		21-Sep-2020	Alkermes Pharma Ireland Limited	IN VITRO METHODS FOR EVALUATING THE IN VIVO EFFECTIVENESS OF DOSAGE FORMS OF
USA	Published		12/729,018	US 2010-0178648 A1	22-Mar-2010		21-Sep-2020	Alkermes Pharma Ireland Limited	IN VITRO METHODS FOR EVALUATING THE IN VIVO EFFECTIVENESS OF DOSAGE FORMS OF
USA	Granted	7390505	10/768,580	US 2004-0258758 A1	30-Jan-2004	24-Jun-2008	30-Jan-2024	Alkermes Pharma Ireland Limited	NANOPARTICULATE TOPIRAMATE FORMULATIONS
USA	Pending		13/189,299		22-Jul-2001		2/2/2024	Alkermes Pharma Ireland Limited	NOVEL FLUTICASONE FORMULATIONS
USA	Published		10/420,927	US 2004-0105889 A1	25-Apr-2003		14-Apr-2023	Alkermes Pharma Ireland Limited	LOW VISCOSITY LIQUID DOSAGE FORMS
USA	APPEAL		11/979,253	US 2006-0152585 A1	31-Oct-2007		14-Apr-2023	Alkermes Pharma Ireland Limited	LOW VISCOSITY LIQUID DOSAGE FORMS
USA	Granted	7842232	10/851,681	US 2010-0255102 A1	24-May-2004	30-Nov-2010	29-Jun-2027	Alkermes Pharma Ireland Limited	STERILIZATION OF DISPERSIONS OF NANOPARTICULATE ACTIVE AGENTS WITH GAMMA RADIATION
USA	APPEAL		10/856,406	US 2005-0042177 A1	21-Jul-2004			Alkermes Pharma Ireland Limited	NOVEL COMPOSITIONS OF SILDENAFIL FREE BASE
USA	APPEAL		10/697,703	US 2004-0156872 A1	31-Oct-2003			Alkermes Pharma Ireland Limited	NOVEL NIMESULIDE COMPOSITIONS
USA	Pending		13/193,545		28-Jul-2011		5/18/2021	Alkermes Pharma Ireland Limited	NOVEL NIMESULIDE COMPOSITIONS
USA	Published		12/282,092	US 2009-0074873 A1	12-Nov-2006		24-Feb-2015	Alkermes Pharma Ireland Limited	NANOPARTICULATE BECLOMETHASONE DIPROPIONATE COMPOSITIONS
USA	APPEAL		10/687,716	US 2004-0141925 A1	31-Oct-2003		16-Jul-2023	Alkermes Pharma Ireland Limited	NOVEL TRIAMCINOLONE COMPOSITIONS
USA	APPEAL		10/701,064	US 2005-0019412 A1	05-Nov-2003			Alkermes Pharma Ireland Limited	NOVEL GLIPIZIDE COMPOSITIONS
USA	Published		10/712,259	US 2004-0115134 A1	14-Nov-2003		22-Jun-2015	Alkermes Pharma Ireland Limited	NOVEL NIFEDIPINE COMPOSITIONS
USA	Published		11/980,720	US 2005-0047209 A1	31-Oct-2007		22-Jun-2015	Alkermes Pharma Ireland Limited	NOVEL NIFEDIPINE COMPOSITIONS
USA	Published		12/292,395	US 2009-0104273 A1	18-Nov-2006		22-Jun-2015	Alkermes Pharma Ireland Limited	NOVEL NIFEDIPINE COMPOSITIONS
USA	Published		10/677,257	US 2004-0101596 A1	03-Oct-2003			Alkermes Pharma Ireland Limited	NOVEL BENZOYL PEROXIDE COMPOSITIONS
USA	Granted	7873930	10/978,695	US 2005-0239725 A1	02-Nov-2004	01-Feb-2011	20-Feb-2028	Alkermes Pharma Ireland Limited	NANOPARTICULATE COMPOSITIONS HAVING A PEPTIDE AS A SURFACE STABILIZER
USA	Published		10/979,792	US 2005-0147694 A1	03-Nov-2004		08-Nov-2024	Alkermes Pharma Ireland Limited	COMPOSITIONS COMPRISING ANTIBODIES AND METHODS OF USING THE SAME FOR TARGETED
USA	Granted	7910677	11/274,887	US 2006-0154918 A1	16-Nov-2006	22-Mar-2011	26-Jan-2025	Alkermes Pharma Ireland Limited	INJECTABLE FORMULATIONS OF NANOPARTICULATE OLANZAPINE
USA	Pending		12/833,238		12-Nov-2006		16-Nov-2025	Alkermes Pharma Ireland Limited	INANOPARTICULATE FORMULATIONS OF OLANZAPINE ESTERS
USA	Pending		13/024,315		08-Feb-2011		16-Nov-2025	Alkermes Pharma Ireland Limited	INANOPARTICULATE FORMULATIONS OF OLANZAPINE ESTERS

Country	Status	Patent Number	Application Number	Publication Number	Filing Date	Issue / Grant Date	Normal Expiry Date	Owner	Short Title / Subject Matter
USA	APPEAL		12/232,836	US 2009-0105366 A1	25-Sep-2008			Alkermes Pharma Ireland Limited	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
USA	Pending		11/833,088		04-Dec-2006		04-Dec-2026	Alkermes Pharma Ireland Limited	NOVEL MOMETASONE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
USA	APPEAL		11/377,650	US 2006-0210639 A1	17-Mar-2006		17-Mar-2026	Alkermes Pharma Ireland Limited	NANOPARTICULATE BISPHOSPHONATE COMPOSITIONS
USA	Published		11/376,554	US 2006-0210638 A1	16-Mar-2006		16-Mar-2026	Alkermes Pharma Ireland Limited	INJECTABLE COMPOSITIONS OF NANOPARTICULATE IMMUNOSUPPRESSIVE COMPOUNDS
USA	Published		11/387,088	US 2006-0216353 A1	23-Mar-2006		23-Mar-2026	Alkermes Pharma Ireland Limited	NANOPARTICULATE CORTICOSTEROID AND ANTIHISTAMINE FORMULATIONS
USA	APPEAL		11/402,264		12-Apr-2008		12-Apr-2026	Alkermes Pharma Ireland Limited	NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS
USA	APPEAL		11/402,257	US 2006-0246141 A1	12-Apr-2008		12-Apr-2026	Alkermes Pharma Ireland Limited	NANOPARTICULATE LIPASE INHIBITOR FORMULATIONS
USA	APPEAL		11/436,887		19-May-2006		19-May-2026	Alkermes Pharma Ireland Limited	NANOPARTICULATE INTEGRIN ANTAGONIST FORMULATIONS
USA	APPEAL		11/980,719		31-Oct-2007		19-May-2026	Alkermes Pharma Ireland Limited	NANOPARTICULATE INTEGRIN ANTAGONIST FORMULATIONS
USA	APPEAL		11/437,838	US 2010-01028439 A1	22-May-2006		22-May-2026	Alkermes Pharma Ireland Limited	NANOPARTICULATE STABILIZED ANTI-HYPERTENSIVE COMPOSITIONS
USA	Published		12/052,436	US 2008-0220074 A1	20-Mar-2008		04-Sep-2023	Alkermes Pharma Ireland Limited	GAMMA RADIATION STERILIZED NANOPARTICULATE DOXETAXEL COMPOSITIONS AND METHOD OF
USA	APPEAL		11/363,256	US 2007-0202190 A1	28-Feb-2006		28-Feb-2026	Alkermes Pharma Ireland Limited	NANOPARTICULATE CARVEDILOL FORMULATIONS
USA	Published		11/275,775	US 2007-0178051 A1	27-Jun-2006			Alkermes Pharma Ireland Limited	STERILIZED NANOPARTICULATE GLUCOCORTICOSTEROID FORMULATIONS
USA	Published		12/071,849	US 2006-0152720 A1	27-Feb-2008		15-Dec-2025	Alkermes Pharma Ireland Limited	NANOPARTICULATE TACROLIMUS FORMULATIONS
USA	Published		12/484,073	US 2008-0252806 A1	12-Jun-2009		15-Dec-2025	Alkermes Pharma Ireland Limited	NANOPARTICULATE TACROLIMUS FORMULATIONS
USA	Pending		13/039,249		02-Mar-2011		21-Dec-2025	Alkermes Pharma Ireland Limited	NANOPARTICULATE BICALUTAMIDE FORMULATIONS
USA	APPEAL		11/361,055	US 2006-0168566 A1	24-Feb-2006		24-Feb-2026	Alkermes Pharma Ireland Limited	NANOPARTICULATE FORMULATIONS OF DOXETAXEL AND ANALOGUES THEREOF
USA	Published		11/354,249	US 2006-0198996 A1	15-Feb-2006			Alkermes Pharma Ireland Limited	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
USA	Published		12/544,197	US 2009-0304041 A1	19-Aug-2009		15-Feb-2026	Alkermes Pharma Ireland Limited	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
USA	Published		11/825,626	US 2006-0163606 A1	05-Jun-2006			Alkermes Pharma Ireland Limited	NANOPARTICULATE CANDESARTAN FORMULATIONS
USA	APPEAL		11/372,227	US 2006-0204586 A1	10-Mar-2006		10-Mar-2026	Alkermes Pharma Ireland Limited	FORMULATIONS OF A NANOPARTICULATE FINASTERIDE, DUTASTERIDE OR TAMUSOLIN
USA	APPEAL		11/446,589	US 2007-0104204 A1	06-Jun-2006		05-Jun-2026	Alkermes Pharma Ireland Limited	NANOPARTICULATE BENIDIPINE COMPOSITIONS
USA	APPEAL		11/446,564	US 2006-0282214 A1	06-Jun-2006		05-Jun-2026	Alkermes Pharma Ireland Limited	NANOPARTICULATE ACETAMINOPHEN FORMULATIONS
USA	Published		11/446,565	US 2006-0275372 A1	06-Jun-2006		05-Jun-2026	Alkermes Pharma Ireland Limited	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
USA	APPEAL		11/448,594	US 2007-01059371 A1	06-Jun-2006		08-Jun-2026	Alkermes Pharma Ireland Limited	NANOPARTICULATE EBASTINE FORMULATIONS
USA	Pending		11/802,427		22-May-2007		22-May-2027	Alkermes Pharma Ireland Limited	NANOPARTICULATE POSACONAZOLE FORMULATIONS
USA	APPEAL		11/481,257		06-Jul-2006		06-Jul-2026	Alkermes Pharma Ireland Limited	NANOPARTICULATE CLARITROMYDIN FORMULATIONS
USA	Published		11/520,059	US 2007-0104732 A1	13-Sep-2006		13-Sep-2026	Alkermes Pharma Ireland Limited	NANOPARTICULATE TADALAFIL FORMULATIONS
USA	Published		11/520,058	US 2007-0148100 A1	13-Sep-2006		13-Sep-2026	Alkermes Pharma Ireland Limited	INJECTABLE FORMULATIONS OF NANOPARTICULATE ARIPIPRAZOLE
USA	Pending		11/761,500		12-Jun-2007		12-Jun-2027	Alkermes Pharma Ireland Limited	NANOPARTICULATE KINASE INHIBITOR FORMULATIONS
USA	APPEAL		11/775,002	US 2008-0213374 A1	09-Jul-2007		09-Jul-2027	Alkermes Pharma Ireland Limited	NANOPARTICULATE FORMULATIONS OF SORAFENIB TOSYLATE
USA	Pending		11/129,807		16-May-2005		16-May-2025	Alkermes Pharma Ireland Limited	NANOPARTICULATE DISPERSION CONTAINING LACTAM COMPOUND
USA	Pending		12/331,052		09-Dec-2008		09-Dec-2028	Alkermes Pharma Ireland Limited	NANOPARTICULATE ANIDULAFUNGIN COMPOSITIONS AND METHODS FOR MAKING THE SAME
USA	Published		12/329,566	2009-0311335 A1	24-Feb-2008		24-Feb-2029	Alkermes Pharma Ireland Limited	COMBINATION OF A TRIPTAN AND AN NSAID
USA	Pending		13/110,647		18-May-2011		18-May-2031	Alkermes Pharma Ireland Limited	NANOPARTICULATE CINACALCET COMPOSITIONS
USA	APPEAL		11/262,672		31-Oct-2005		31-Oct-2025	Alkermes Pharma Ireland Limited	CONTROLLED RELEASE COMPOSITIONS COMPRISING A COMBINATION OF ISOSORBIDE DINITRATE AND
USA	Published		11/373,629	US 2007-01068791 A1	10-Mar-2006		31-Oct-2025	Alkermes Pharma Ireland Limited	CONTROLLED RELEASE COMPOSITIONS COMPRISING A COMBINATION OF ISOSORBIDE DINITRATE AND
USA	Published		11/569,489	US 2008-0263043 A1	01-Feb-2008		26-Jan-2026	Alkermes Pharma Ireland Limited	CONTROLLED RELEASE COMPOSITIONS COMPRISING AN ANTI-PSYCHOTIC AGENT
USA	Published		11/529,693	US 2006-0263596 A1	11-Jan-2006		11-Jan-2026	Alkermes Pharma Ireland Limited	CONTROLLED RELEASE COMPOSITIONS COMPRISING AN AGCYNAMIDE
USA	Pending		11/568,841		29-Jun-2007		14-Feb-2026	Alkermes Pharma Ireland Limited	CONTROLLED RELEASE COMPOSITIONS COMPRISING LEVETIRACETAM
USA	Pending		11/571,379		12-Apr-2008		12-Apr-2026	Alkermes Pharma Ireland Limited	CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN FOR THE TREATMENT OF A
USA	APPEAL		11/568,202	US 2007-0122481 A1	09-Nov-2006		01-Nov-2019	Alkermes Pharma Ireland Limited	MODIFIED RELEASE COMPOSITIONS COMPRISING A FLUOROCYTIDINE DERIVATIVE FOR THE TREATMENT
USA	Pending		11/568,925		18-Nov-2006		01-Nov-2019	Alkermes Pharma Ireland Limited	MODIFIED RELEASE LIXOPROFEN COMPOSITIONS
USA	Published		11/422,226	US 2008-0118556 A1	05-Jun-2006		01-Nov-2019	Alkermes Pharma Ireland Limited	MODIFIED RELEASE OF COMPOSITIONS CONTAINING A COMBINATION OF CARBIDOPA, LEVODOPA AND
USA	Granted	5505962	08/307,392		16-Sep-1994	09-Apr-1995	09-Apr-2013	Alkermes Pharma Ireland Limited	CONTROLLED RELEASE PHARMACEUTICAL FORMULATION
USA	Granted	5641745	08/479,509		07-Jun-1995	24-Jun-1997	07-Jun-2015	Alkermes Pharma Ireland Limited	CONTROLLED RELEASE BIODEGRADABLE MICRO- AND NANOSPHERES CONTAINING CYCLOSPORIN
USA	Granted	5364620	07/921,459		28-Jul-1992	15-Nov-1994	15-Nov-2011	Alkermes Pharma Ireland Limited	CONTROLLED ABSORPTION DILTIAZEM FORMULATION FOR ONCE-DAILY ADMINISTRATION
USA	Granted	5618245	08/334,694		04-Nov-1994	01-Apr-1997	01-Apr-2014	Alkermes Pharma Ireland Limited	CONTROLLED ABSORPTION DILTIAZEM FORMULATION FOR ONCE-DAILY ADMINISTRATION
USA	Granted	5339504	08/064,401		19-May-1993	08-Aug-1994	22-Jul-2012	Alkermes Pharma Ireland Limited	DILTIAZEM FORMULATION AND METHODS OF TREATMENT
USA	Licensed	5370679	08/073,851		07-Jun-1993	06-Dec-1994	06-Dec-2011	Alkermes Pharma Ireland Limited	FORMULATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
USA	Licensed	5540938	08/528,165		24-Oct-1994	30-Jul-1996	30-Jul-2013	Alkermes Pharma Ireland Limited	FORMULATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
USA	Licensed	5580580	08/479,506		07-Jun-1995	03-Dec-1996	03-Dec-2013	Alkermes Pharma Ireland Limited	FORMULATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
USA	Licensed	5533995	08/244,094		13-May-1994	09-Jul-1996	09-Jul-2013	Alkermes Pharma Ireland Limited	PASSIVE TRANSDERMAL DEVICE WITH CONTROLLED DRUG DELIVERY
USA	Licensed	6069339	09/477,595		25-Nov-1997	23-May-2000	25-Nov-2017	Alkermes Pharma Ireland Limited	ORA MORPHINE MULTIPARTICULATE FORMULATION
USA	Licensed	6229338	09/566,636		08-May-2000	08-May-2001	01-Nov-2019	Alkermes Pharma Ireland Limited	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
USA	Licensed	6730325	09/680,425	US 2002-0064907 A1	07-May-2001	04-May-2004	01-Nov-2019	Alkermes Pharma Ireland Limited	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPENIDATE
USA	Licensed	6902742	10/331,754	US 2003-0123237 A1	30-Dec-2002	07-Jun-2005	01-Nov-2019	Alkermes Pharma Ireland Limited	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPENIDATE
USA	Licensed	6739336	10/354,483	US 2003-0170304 A1	30-Jun-2003	21-Sep-2004	01-Nov-2019	Alkermes Pharma Ireland Limited	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPENIDATE
USA	APPEAL		10/827,699	US 2004-0187405 A1	19-Apr-2004		01-Nov-2019	Alkermes Pharma Ireland Limited	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPENIDATE
USA	Published		11/372,857	US 2006-0240105 A1	10-Mar-2006		01-Nov-2019	Alkermes Pharma Ireland Limited	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPENIDATE
USA	Granted	7465462	09/744,169		19-Apr-2001	16-Dec-2006	16-May-2020	Alkermes Pharma Ireland Limited	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR FORMULATIONS
USA	Granted	7021183	10/492,098	US 2005-0003550 A1	08-Apr-2004	04-Apr-2006	09-Oct-2022	Alkermes Pharma Ireland Limited	APPARATUS AND METHOD FOR CONCURRENTLY MONITORING ACTIVE RELEASE AND PHYSICAL
USA	Pending		12/628,001	US 2010-0272807	25-Nov-2005			Alkermes Pharma Ireland Limited	SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS
USA	Pending		12/628,085	US 2010-0272796	25-Nov-2005			Alkermes Pharma Ireland Limited	SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS
USA	Pending		12/628,036	US 2010-0272795	25-Nov-2005			Alkermes Pharma Ireland Limited	SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS
USA	Published		11/568,891	US 2010-0136106 A1	15-Jun-2010		07-Jun-2026	Alkermes Pharma Ireland Limited	MODIFIED RELEASE FAMCICLOVIR COMPOSITIONS
USA	Published		11/569,481	US 2009-0287597 A1	21-Nov-2006			Alkermes Pharma Ireland Limited	MODIFIED RELEASE TICLOPIDINE COMPOSITIONS
USA	Pending		13/044,225		09-Mar-2011			Alkermes Pharma Ireland Limited	ALCOHOL RESISTANT ENTERIC PHARMACEUTICAL COMPOSITIONS
United States	Granted	US 5,841,745	08/479,509				2-Apr-2016	Alkermes Pharma Ireland Limited	OR BIODEGRADABLE MICRO- AND NANOSPHERES CONTAINING CYCLOSPORIN
USA	Granted	6909626	10/268,528	US 2003-0137067 A1	11-Oct-2002	21-Jun-2005	25-Dec-2022	Alkermes Pharma Ireland Limited	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE
USA	Pending		12/407,694		19-Mar-2006		19-Mar-2029	Alkermes Pharma Ireland Limited	COMPOSITIONS FOR SITE-SPECIFIC DELIVERY OF IMATINIB MESYLATE AND METHODS OF USE
USA	Published		11/297,377	US 2006-0161112 A1	08-Dec-2005		08-Dec-2025	Alkermes Pharma Ireland Limited	TOPIRAMATE PHARMACEUTICAL COMPOSITION
USA	Pending		11/571,377		14-Jun-2008		02-Mar-2026	Alkermes Pharma Ireland Limited	CONTROLLED RELEASE COMPOSITIONS COMPRISING HETEROCYCLIC AMIDE DERIVATIVE
USA	Pending		11/568,698		03-Nov-2006		13-Apr-2026	Alkermes Pharma Ireland Limited	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING PROSTAGLANDIN
USA	Pending		11/569,206		16-Nov-2006		06-May-2026	Alkermes Pharma Ireland Limited	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING VITAMIN C2
USA	Published		11/568,825	US 2009-0269400 A1	11-May-2009		16-May-2026	Alkermes Pharma Ireland Limited	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN
USA	Published		11/568,835	US 2009-0287596 A1	23-May-2006		23-May-2026	Alkermes Pharma Ireland Limited	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A PLATELET
USA	Granted	5641515	08/474,161		07-Jun-1995	24-Jun-1997	07-Jun-2015	Alkermes Pharma Ireland Limited	CONTROLLED RELEASE BIODEGRADABLE NANOPARTICLES CONTAINING INSULIN
USA	Pending		11/671,276		06-Feb-2007		06-Feb-2027	Alkermes Pharma Ireland Limited	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING CEFIDITOREN
USA	Published		11/672,283	US 2011-0008436 A1	07-Feb-2007			Alkermes Pharma Ireland Limited	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING ARYL-HETEROCYCLIC

Country	Status	Patent Number	Application Number	Publication Number	Filing Date	Issue / Grant Date	Normal Expiry Date	Owner	Short Title / Subject Matter
USA	Published		11/479,013	US 2010-0247636 A1	30-Jun-2006		30-Jun-2026	Alkermes Pharma Ireland Limited	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING NILVADIPINE
USA	Published		11/776,770	US 2008-0317843 A1	12-Jul-2007		12-Jul-2027	Alkermes Pharma Ireland Limited	NANOPARTICULATE FORMULATIONS OF MODAFINIL
USA	Published		12/049,046	US 2008-0226734 A1	14-Mar-2008		14-Mar-2028	Alkermes Pharma Ireland Limited	COMBINATION OF A NARCOTIC AND NON-NARCOTIC ANALGESIC
USA	Published		11/768,154	US 2008-0113025 A1	25-Jun-2007		25-Jun-2027	Alkermes Pharma Ireland Limited	COMPOSITIONS COMPRISING NANOPARTICULATE NAPROXEN AND CONTROLLED RELEASE
USA	Published		11/768,189	US 2008-0102121 A1	25-Jun-2007		25-Jun-2027	Alkermes Pharma Ireland Limited	COMPOSITIONS COMPRISING NANOPARTICULATE MELOXICAM AND CONTROLLED RELEASE
USA	Granted	5332113	07/758,964		10-Sep-1991	26-Sep-1994		Alkermes Pharma Ireland Limited	CAP ASSEMBLY
USA	Published		10/528,727	US 2006-0104909 A1	05-Dec-2005		23-Sep-2023	APIL & VERION INC	ABUSE RESISTANT PHARMACEUTICAL COMPOSITIONS
USA	Pending		12/757,005		06-Apr-2010			Alkermes Pharma Ireland Limited	DRUG DELIVERY COMPOSITION (NANO OSMOTIC PUMP)
USA	Pending		12/757,024		06-Apr-2010			Alkermes Pharma Ireland Limited	CONTROLLED RELEASE CLOZAPINE COMPOSITIONS
USA	Published		12/209,728	2009-0149479 A1	12-Sep-2008		12-Sep-2028	Alkermes Pharma Ireland Limited	DOSING REGIMEN
USA	Pending		12/897,924		04-Mar-2008		04-Mar-2029	Alkermes Pharma Ireland Limited	STABLE LIQUID FORMULATIONS OF ANTI-INFECTION AGENTS AND ADJUSTED ANTI-INFECTION AGENT
USA	Published		12/788,196	US 2010-0316725 A1	26-May-2010		26-May-2030	Alkermes Pharma Ireland Limited	REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
USA	Granted	5242406	07/809,195		16-Dec-1991	07-Sep-1993	16-Dec-2011	Alkermes Pharma Ireland Limited	DEVICE & METHOD FOR DISPENSING A LIQUID PARTICULARLY USEFUL FOR DELIVERING MEDICAMENTS
USA	Granted	5359632	07/759,006		12-Sep-1991	18-Oct-1994	18-Oct-2011	Alkermes Pharma Ireland Limited	TRANSDERMAL DRUG DELIVERY DEVICE
USA	Granted	5380272	08/077,146		16-Jun-1993	10-Jan-1995	15-Jun-2012	Alkermes Pharma Ireland Limited	TRANSCUTANEOUS DRUG DELIVERY APPLICATOR
United States	Granted	US 5871125	08/097,692				5-Sep-2016	Alkermes Pharma Ireland Limited	Liquid delivery pumping device
USA	Granted	6312409	09/831,648		07-Sep-1999	06-Nov-2001	07-Sep-2019	Alkermes Pharma Ireland Limited	DEVICE FOR GENERATING A PULSATILE FLUID DRUG FLOW
USA	Granted	6078642	987404		23-Dec-1997	20-Jun-2000	23-Dec-2017	Alkermes Pharma Ireland Limited	IMPROVED ELECTRODE AND IONTOPHORETIC DEVICE AND METHOD
USA	Granted	6157658	08/987,388		23-Dec-1997	05-Dec-2000	23-Dec-2017	Alkermes Pharma Ireland Limited	DEVICE FOR THE DELIVERY OF A SUBSTANCE TO A SUBJECT AND IMPROVED ELECTRODE ASSEMBLY
USA	Granted	6317630	09/239,934		26-Jan-1999	13-Nov-2001	29-Jan-2015	Alkermes Pharma Ireland Limited	DRUG DELIVERY DEVICE
USA	Granted	0454,194 S	29/135,576		25-Jan-2001	06-Mar-2002	06-Mar-2016	Alkermes Pharma Ireland Limited	DRUG RECONSTITUTION AND INJECTION DEVICE
USA	Granted	6719719	09/863,539	US 2002-0004643 A1	23-May-2001	13-Apr-2004	23-May-2021	Alkermes Pharma Ireland Limited	SPIKE FOR LIQUID TRANSFER DEVICE, LIQUID TRANSFER DEVICE INCLUDING SPIKE AND METHOD OF
USA	Licensed	5927288	08/183,482		18-Jan-1994	18-Jan-1996	18-Jan-2014	Alkermes Pharma Ireland Limited	INTRADERMAL DRUG DELIVERY DEVICE
USA	Licensed	5967501	08/847,954		19-Aug-1996	07-Dec-1999	07-Dec-2016	Alkermes Pharma Ireland Limited	INTRADERMAL DRUG DELIVERY DEVICE
USA	Licensed	5914020	08/708,230		08-Sep-1996	29-Sep-1998	06-Sep-2016	Alkermes Pharma Ireland Limited	MEDICAMENT DELIVERY DEVICE
USA	Licensed	5893601	08/763,511		10-Dec-1996	12-Jan-1999	10-Dec-2016	Alkermes Pharma Ireland Limited	CARTRIDGE-BASED DRUG DELIVERY DEVICE
USA	Licensed	6261272	09/202,176		01-Jun-1999	17-Jul-2001	04-Jun-2017	Alkermes Pharma Ireland Limited	NEEDLE FOR SUBCUTANEOUS DELIVERY OF FLUIDS
USA	Licensed	6349095	09/778,332		06-Feb-2001	12-Feb-2002	04-Jun-2017	Alkermes Pharma Ireland Limited	NEEDLE AND METHOD FOR DELIVERY OF FLUIDS
USA	Licensed	6530600	09/577,038		23-May-2000	11-Mar-2003	06-May-2018	Alkermes Pharma Ireland Limited	SUBCUTANEOUS DRUG DELIVERY DEVICE WITH IMPROVED FILLING SYSTEM
USA	Licensed	6169682	09/072,675		05-May-1998	13-Feb-2001	05-May-2018	Alkermes Pharma Ireland Limited	SUBCUTANEOUS DRUG DELIVERY DEVICE WITH IMPROVED FILLING SYSTEM
USA	Licensed	6500150	09/103,716		23-Jun-1998	31-Dec-2002	12-Feb-2019	Alkermes Pharma Ireland Limited	PRE-FILLED DRUG-DELIVERY DEVICE AND METHOD OF MANUFACTURE AND ASSEMBLY OF SAME
USA	Licensed	6824529	09/836,105	US 2002-0010423 A1	17-Apr-2001	30-Nov-2004	17-Apr-2021	Alkermes Pharma Ireland Limited	PRE-FILLED DRUG-DELIVERY DEVICE AND METHOD OF MANUFACTURE AND ASSEMBLY OF SAME
USA	Licensed	6843782	09/836,964	US 2001-0025188 A1	18-Apr-2001	18-Jan-2005	07-Oct-2018	Alkermes Pharma Ireland Limited	PRE-FILLED DRUG-DELIVERY DEVICE AND METHOD OF MANUFACTURE AND ASSEMBLY OF SAME
USA	Licensed	6275717	09/102,840		23-Jun-1998	14-Aug-2001	23-Jun-2018	Alkermes Pharma Ireland Limited	METHODS OF CALIBRATING AND TESTING A SENSOR FOR IN VIVO MEASUREMENT OF AN ANALYTE AND
USA	Licensed	6003648	09/102,841		23-Jun-1998	14-Dec-1999	23-Jun-2018	Alkermes Pharma Ireland Limited	DRUG DELIVERY KIT AND METHOD OF PACKAGING THE SAME
USA	Licensed	6585707	09/815,629	US 2001-0068262 A1	20-May-1999	01-Jul-2003	20-May-2019	Alkermes Pharma Ireland Limited	IMPROVED ADHESIVE SYSTEM FOR MEDICAL DEVICES
USA	Licensed	6595956	09/275,464		23-Mar-1999	22-Jul-2003	23-Mar-2019	Alkermes Pharma Ireland Limited	IMPROVED DRUG DELIVERY DEVICE
USA	Licensed	7384413	10/461,040	US 2003-0239496 A1	13-Jun-2003	10-Jun-2008	23-Mar-2019	Alkermes Pharma Ireland Limited	DEVICE FOR MEASURING VOLUME OF DRUG
USA	Licensed		12/121,545		15-May-2008		23-Mar-2019	Alkermes Pharma Ireland Limited	IMPROVED DRUG DELIVERY DEVICE
USA	Licensed		13/184,479		15-Jul-2011			Alkermes Pharma Ireland Limited	IMPROVED DRUG DELIVERY DEVICE
USA	Licensed		13/184,473		15-Jul-2011			Alkermes Pharma Ireland Limited	IMPROVED DRUG DELIVERY DEVICE
USA	Licensed	6520641	09/415,961		12-Oct-1999	18-Feb-2003	12-Oct-2019	Alkermes Pharma Ireland Limited	METHOD AND DEVICE FOR ENTRAPPING GAS WITHIN A LIQUID DRUG CONTAINER
USA	Licensed	7530694	09/883,026		17-Jun-2001	12-May-2009	03-Oct-2023	Alkermes Pharma Ireland Limited	NEEDLE DEVICE AND METHOD AND OPERATION THEREOF
USA	Licensed	6572740	08/832,179	27068	11-Apr-2001	03-Jun-2003	11-Apr-2021	Alkermes Pharma Ireland Limited	ELECTROLYTIC CELL
USA	Granted	6759057	07/923,182		13-Mar-1989	06-Jul-2004	06-Jul-2021	Alkermes Pharma Ireland Limited	METHODS AND COMPOSITIONS USING LIPOSOME-ENCAPSULATED NON-STEROIDAL ANTI-INFLAMMATORY
USA	Granted	5948441	08/967,923		08-Jan-1995	07-Sep-1999	07-Sep-2016	Alkermes Pharma Ireland Limited	METHOD FOR SIZE SEPARATION OF PARTICLES
USA	Granted	5629873	08/442,080		16-May-1995	06-May-1997	16-May-2015	Alkermes Pharma Ireland Limited	NOVEL EMULSIONS
USA	Granted	5523232	08/137,571		14-Oct-1993	11-Jun-1996	14-Oct-2013	Alkermes Pharma Ireland Limited	METHOD FOR ENTRAPMENT OF CATIONIC SPECIES IN LAMELLAR VESICLES
USA	Granted	5718626	08/689,689		12-Feb-1996	10-Feb-1998	12-Feb-2016	Alkermes Pharma Ireland Limited	METHOD OF SEPARATING MATERIALS FROM LIPOSOMES OR LIPID COMPLEXES
USA	Granted	5662930	08/433,665		04-May-1995	02-Sep-1997	04-May-2015	Alkermes Pharma Ireland Limited	REDUCTION OF LIPOSOME INDUCED ADVERSE PHYSIOLOGICAL REACTIONS
USA	Granted	5514214	08/247,058		20-May-1994	25-Mar-1997	20-May-2014	Alkermes Pharma Ireland Limited	REDUCTION OF LIPOSOME INDUCED ADVERSE PHYSIOLOGICAL REACTIONS
USA	Granted	5,591,123	08/381,141				07-Jan-2014	Alkermes Pharma Ireland Limited	Programmable control mounting system for transdermal drug applicator
USA	Granted	5,369,483	07/949,721				25-Oct-2011	Alkermes Pharma Ireland Limited	Disposable transdermal drug applicator
USA	Granted	5,372,579	08/204,784				13-Dec-2011	Alkermes Pharma Ireland Limited	Pulsating transdermal drug delivery system

SCHEDULE B

Alkermes Irish Patent Schedule

September 2011

Case #: 000166.0051

Title: MICROENCAPSULATED 3-PIPERIDINYL-SUBSTITUTED 1,2-BENZISOXAZOLES AND 1,2-BENZISOTHIAZOLES

Owner: ALKERMES, INC. and JANSSEN PHARMACEUTICA

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
Ireland		EPO	Granted	95900721.2	11-Nov-1994	0729357	2-Feb-2005	11-Nov-2014

Case #: 000166.0053

Title: PREPARATION OF BIODEGRADABLE MICROPARTICLES CONTAINING A BIOLOGICALLY ACTIVE AGENT

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent#	Issue Date	Expiration Date
Ireland	02	PCT	Granted	95 901 961.3	18-Nov-1994	0729353	06-Feb-2002	18-Nov-2014

Case #: 000166.0063

Title: PREPARATION OF EXTENDED SHELF-LIFE BIODEGRADABLE, BIOCOMPATIBLE MICROPARTICLES CONTAINING A BIOLOGICALLY ACTIVE AGENT

Owner: ALKERMES, INC. and JANSSEN PHARMACEUTICA

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
Ireland		EPO/DIV	Granted	02075905.6	06-May-1997	1210942	21-Mar-2007	6-May-2017
Ireland		EPO	Granted	97923063.8	06-May-1997	0904063	4-Sep-2002	6-May-2017

Case #: 000166.0070

Title: METHOD FOR PREPARING MICROPARTICLES HAVING A SELECTED RELEASE PROFILE

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
Ireland	00	EPP	Granted	99965212.6	10-Dec-1999	1140029	09-Nov-2005	10-Dec-2019

Alkermes Irish Patent Schedule

September 2011

Case #: 000166.0073

Title: PREPARATION OF INJECTABLE SUSPENSIONS HAVING IMPROVED INJECTABILITY

Owner: ALKERMES PHARMA IRELAND LIMITED AND ALKERMES CONTROLLED THERAPEUTICS, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
Ireland	00	EPP	Granted	01928628.5	19-Apr-2001	1283699	06-Jun-2007	19-Apr-2021

Case #: 000166.0075

Title: APPARATUS AND METHOD FOR PREPARING MICROPARTICLES

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
Ireland	00	EPP	Granted	00991722.0	03-Nov-2000	1231898	27-Dec-2006	03-Nov-2020

Case #: 000166.0077

Title: PROCESS FOR ADJUSTING POLYMER MOLECULAR WEIGHT POLYMER MICROPARTICLES

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
Ireland	00	EPP	Granted	01928630.1	19-Apr-2001	1282404	02-Jul-2008	19-Apr-2021

Alkermes Irish Patent Schedule

September 2011

Case #: 000166.0098

Title: APPARATUS AND METHOD FOR PREPARING MICROPARTICLES USING IN-LINE SOLVENT EXTRACTION

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
Ireland	00	EPP	Granted	00990484.8	03-Nov-2000	1242053	12-Jan-2005	03-Nov-2020

Case #: 4000.3005

Title: Methods for Administering Aripiprazole

Owner: ALKERMES, INC.

Country	Sub Case	Case Type	Status	Application #	Filing Date	Patent #	Issue Date	Expiration Date
Ireland		EPP	Granted	04779411.0	29-Jul-2004	1660037	31-Aug-2011	29-Jul-2024